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Abstract 
	  
The protein kinase Polo-like kinase-1 (PLK1) is an essential driver of mitosis and is 
oncogenic when expressed at elevated levels. Therefore, a number of inhibitors of 
PLK1 have been developed as potential anti-cancer therapeutic agents. While these 
inhibitors undergo clinical evaluation there has been evidence to show that they are less 
effective in killing cancer cells expressing the transcription factor p53. Normally, p53 is 
a potent tumour suppressor that has a classical role in orchestrating inhibition of cancer 
cell growth. However, under some circumstances p53 appears to protect cancer cells, 
due to cells undergoing a reversible growth arrest. This may allow cells to recover post-
treatment. Here, it has been shown that a proportion of p53 competent cells treated with 
PLK1 inhibitors undergo a G1/S arrest. This is mediated by p53 and may offer 
protection to these cells. Application of PLK1 inhibitors also gives rise to DNA 
damage, induces p53, promotes increased p53 phosphorylation, and causes activation of 
downstream targets, such as p21. Inhibiting the DNA damage-activated protein kinases 
ATM and ATR prior to treatment with PLK1 inhibitors alleviates the activation of p53. 
Interestingly, the resulting duration of mitotic arrest from inhibition of PLK1 is 
markedly shorter in cells that are p53 competent. Study of the centrosomes after PLK1 
inhibition highlighted that centrosome separation is more greatly impaired in cells 
deficient of p53. Furthermore, use of an inhibitor of Eg5, a motor protein involved in 
centrosome separation, resulted in similar phenotypes to that observed with inhibitors of 
PLK1. This suggests p53 has a potentially novel role in centrosome separation and has 
highly important implications for treatment with PLK1, and perhaps Eg5, inhibitors. 
This work suggests that screening of individual patients for the p53 status of their 
cancer could be a major consideration in prescribing use of these inhibitors. 
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1.1. Polo-Like Kinases 
 
1.1.1. Background to Polo-Like Kinases 
	  
Polo, a Drosophila melanogaster gene product, in which mutations were found to give 
rise to abnormal spindle poles during mitosis, was first cloned in 1988 (Sunkel and 
Glover, 1988). Polo kinase is highly conserved from yeast to humans, with eukaryotes 
having one or more orthologue. CDC5 was recognised as the polo-like kinase (PLK) in 
S. cerevisiae (fission yeast) (Kitada et al., 1993) and Plo1 was discovered in S. pombe 
(budding yeast) (Ohkura, Hagan and Glover, 1995). The PLK family members in X. 
laevis are Plx 1, 2 and 3, with Plx2 and Plx3 being characterised several years after the 
initial discovery of Plx1 (Kumagai and Dunphy, 1996; Duncan et al., 2001). In 
mammals, five homologues of polo have been discovered, named PLK1 through to 
PLK5 (Simmons et al., 1992; Fode et al., 1994; Golsteyn et al., 1994; Donohue et al., 
1995; Andrysik et al., 2010) and these proteins are represented in Figure 1.1. The PLKs 
are a family of serine/threonine protein kinases that have essential roles in several stages 
of cell cycle progression, through cooperation with Cyclin-dependent kinases (CDKs) 
(Strebhardt and Ullrich, 2006). They are characterised by a conserved N-terminal 
serine/threonine kinase domain (with the exception of PLK5) and C-terminal polo box 
domain, which consists of two polo boxes in the case of PLK1, PLK2, PLK3 and PLK5 
or a cryptic polo box domain as seen in PLK4 (Strebhardt, 2010; Slevin et al., 2012). 
PLK1 is the most highly conserved and best characterised of the PLKs, with essential 
roles in mitosis, and is the main focus of this thesis. However, a brief overview of the 
roles of the other four PLKs is given below, before moving on to a more in depth 
discussion of PLK1.  
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Figure 1.1. The human PLK family. The five members of the PLK family are represented in the 
schematic. As can be seen, PLK1, PLK2, PLK3 and PLK4 all possess a protein kinase domain (purple) in 
the N-terminus. The amino acid sequence identity of the kinase domain is represented as a percentage of 
similarity to PLK1. The activity of PLK1 is enhanced by phosphorylation of threonine 210 (T210) in the 
activating T-loop in the kinase domain. The threonine residues equivalent to threonine 210 are conserved 
in PLK2, PLK3 and PLK4, as indicated in the figure. Due to an in-frame stop codon, PLK5 only contains 
the final fragment of the kinase domain. All five of the PLKs contain a polo box domain (PBD) which 
comprises two polo boxes (PB 1 and PB 2) (represented in green) in PLK1, PLK2, PLK3 and PLK5. 
PLK4 contains a cryptic polo box (orange) as well as C-terminal polo box (green). Again, as with the 
kinase domain, the percentage of sequence similarity of the polo boxes of each PLK is shown in relation 
to the polo boxes of PLK1. Each protein is a different size, as can be seen from the total number of amino 
acids (aa) each protein is composed of, which is indicated on the right of each structure. The information 
in the figure is adapted from (Lee et al., 2014).  
PLK4%
PLK5%
970%aa%
336%aa%
265%12%
Cryp3c%PBD%38%%
PLK3% 646%aa%
314%62%
41%% 41%%53%%
464% 542% 563% 545%
204% 263%264% 336%
Kinase%Domain% Polo%Box%Domain%
PLK1% 603%aa%
53% 305% 411% 489% 511% 592%
T210%
PB%1% PB%2%
PLK2% 685%aa%
82% 334%
45%% 38%%53%%
504% 582% 602% 685%
T239%
T219%
580% 808% 884% 969%
67%% 25%%
T170%
23%%PB%1%
21%%PB%2%
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1.1.2. Polo-like Kinase-2 
 
The PLK2 gene maps to chromosome 5 at 5q11.2 and encodes the Polo-like kinase-2 
(PLK2) protein. Polo-like kinase-2 (also known as SNK (serum–inducible kinase)) is 
thought to function as a tumour suppressor. PLK2 was reported to be transcriptionally 
downregulated in B-cell neoplasms. Silencing of PLK2 occurs frequently in Burkitt 
lymphoma as well as other types of B-cell neoplasms. The silencing was found to be 
specific to malignant B cells, with ectopic expression of PLK2 in Burkitt lymphoma cell 
lines resulting in apoptosis, therefore implicating tumour suppressive roles for PLK2 
(Syed et al., 2006). PLK2 is located at the centrosomes during the G1 and S phases of 
the cell cycle and has been shown to be required for centriole duplication (Warnke et 
al., 2004; Cizmecioglu et al., 2008). It has been described as a transcriptional target of 
p53 and is also thought to be involved in activation of a G2/M checkpoint (Burns et al., 
2003). 
 
1.1.3. Polo-like Kinase-3  
 
Polo-like kinase-3 (also known as CNK (cytokine-inducible kinase), PRK 
(proliferation-related kinase) and FNK) is also thought to have tumour suppressive 
roles. The PLK3 gene is located at 1p34.1 and PLK3 was firstly identified as a 
fibroblast growth factor 1 induced immediate entry gene (Donohue et al., 1995). The 
cell cycle dependent expression of PLK3 is still unclear, as some studies detect similar 
levels of PLK3 expression throughout the cell cycle (Holtrich et al., 2000; Bahassi et 
al., 2002), some see a peak at G1 (Zimmerman and Erikson, 2007), some have found 
the levels peak at late S/ G2 (Ouyang et al., 1997) and some have observed peak levels 
in mitosis (Chase et al., 1998).  PLK3 has been suggested to function at the G1/S 
transition (Zimmerman and Erikson, 2007) and in the Golgi fragmentation pathway 
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(Ruan et al., 2004; Lopez-Sanchez, Sanz-Garcia and Lazo, 2009). Like PLK2, PLK3 is 
a transcriptional target of p53. When ionising radiation is applied, p53 transactivates 
PLK3 expression (Jen and Cheung, 2005). In addition to PLK3 being a transcriptional 
target of p53, p53 has been shown to be phosphorylated by PLK3. In response to DNA 
damage or hydrogen peroxide exposure, PLK3 was found to physically interact with 
p53 and phosphorylate p53 at serine 20 (Xie, Wang, et al., 2001; Xie, Wu, et al., 2001). 
Studies have shown that PLK3 expression is negatively associated with certain cancers. 
Supporting the idea of PLK3 having tumour suppressive roles are the findings that 
PLK3 mRNA expression is downregulated in lung cancer (Li et al., 1996) and PLK3 
null mice are viable, but develop tumours in various organs (Yang et al., 2008). PLK3 
was also found to be downregulated in osteosarcomas, with increased expression of 
PLK3 leading to inhibition of cell proliferation and tumorigenesis, and association with 
improved patient survival (Lv et al., 2015). In addition to roles in cancer, PLK3 has also 
been linked to roles in prion disease. PLK3 was shown to assist in the clearance of the 
pathogenic PrP(Sc) protein that occurs in prion disease, and this study suggested that 
recovering PLK3 at early stages of prion infection may be a potential treatment to 
prevent accumulation of this infectious protein in the brain (Wang et al., 2015). 
 
1.1.4. Polo-like Kinase-4 
 
Polo-like kinase-4 (also known as SAK (SNK/PLK-akin kinase) and STK18), is 
structurally the most divergent PLK and is	  encoded by the PLK4 gene which maps to 
chromosome 4 at 4q28.1. Unlike the other PLKs, which contain two polo box domains, 
PLK4 has two tandem repeat cryptic polo boxes and also contains a third C-terminal 
polo box (Slevin et al., 2012). PLK4 has critical roles in centriole duplication 
(Bettencourt-Dias et al., 2005; Habedanck et al., 2005) and the expression levels of 
PLK4 are similar to PLK1, with levels increasing gradually from S phase through to 
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mitosis (Swallow et al., 2005). One study showed that unlike PLK3, which is activated 
by p53, PLK4 is repressed by p53. PLK4 was shown to be downregulated by wild type 
p53 in several tumour models, but although three putative p53 binding sites were 
discovered in the PLK4 promoter, p53 was not observed to bind to these sites, 
suggesting repression of PLK4 was not through direct binding of p53 to the PLK4 
promoter (Li et al., 2005). The role of PLK4 in cancer is still not clear, however PLK4 
null mice are not viable and heterozygous mice develop spontaneous tumours, mainly in 
the liver (Swallow et al., 2005). PLK4 has been implicated as a tumour suppressor in a 
study where PLK4 expression declined during the progression from non-tumourous 
liver tissue to hepatocellular carcinoma (Pellegrino et al., 2010). However, other studies 
have found that PLK4 expression is linked to cancer progression. In breast cancer PLK4 
was found to be expressed at a higher level in breast cancer tissue compared to normal 
breast tissue and high levels of PLK4 was shown to be a detrimental prognostic factor 
for overall survival (Zhenhua Li et al., 2016). In addition, overexpression of PLK4 in 
Drosophila neuroblasts can promote tumorigenesis (Basto et al., 2008).  
 
1.1.5. Polo-like Kinase-5 
 
Polo-like kinase-5 (PLK5) is the least researched of the PLK family. The PLK5 gene 
maps to 19p13.3. PLK5 is more similar to PLK2 and PLK3 than PLK1 or PLK4, based 
on DNA and protein level sequence similarities. However, PLK5 lacks a functional 
kinase domain. An in-frame stop codon in exon 6 disrupts the kinase domain of PLK5. 
However, a conserved ATG in the boundary of exons 6 and 7 leads to expression of a 
short protein that contains the final fragment of the kinase domain, the linker region and 
two polo-boxes. It is expressed in the eye, brain and ovary of the mouse (de Cárcer et 
al., 2011). PLK5 is activated in response to DNA damage and has three p53 binding 
motifs in the promoter region (Andrysik et al., 2010). It has been suggested that PLK5 
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is a stress-induced protein, responding to a number of stress signals, such as DNA 
damaging or microtubule disrupting agents. Like PLK3, overexpressing PLK5 results in 
a G1 cell cycle arrest and apoptosis (Andrysik et al., 2010). Interestingly, PLK5 has 
been implicated in the formation of neurite processes, and in many brain tumours PLK5 
is found to be downregulated. Reintroduction of PLK5 in glioblastoma multiforme cells 
causes cell death, suggesting a tumour suppressive role for PLK5 (de Cárcer et al., 
2011). More recent studies have associated a three nucleotide deletion near the C-
terminus of PLK5 with lymphatic metastasis in clear cell renal cell carcinoma. This 
suggests PLK5 deletion status could be used as an early biomarker for clear cell renal 
cell carcinoma metastasis (Zhongjun Li et al., 2016). 
 
1.2. Polo-like Kinase-1 
 
PLK1, the founding member and best characterised of the PLK family was first 
described in 1994 (Golsteyn et al., 1994). The sections below give an overview of 
PLK1 including its structure, function, regulation, role in cancer and inhibitors being 
developed to target its activity. 
 
1.2.1. PLK1 Structure 
 
In 1994 a human protein kinase with a high sequence similarity to polo (Drosophila) 
and CDC5 (S. cerevisiae) was characterised (Golsteyn et al., 1994). This protein kinase 
was referred to as PLK1. The PLK1 gene is located at 16p12.2 (Xu et al., 2013) and 
encodes the PLK1 protein, which is 603 amino acids in length and has a molecular mass 
of approximately 68kDa. As with other members of the PLK family, PLK1 has an N-
terminal catalytic domain and C-terminal polo box domain (PBD), comprising two polo 
boxes. PLK1 localises to numerous structures involved in mitosis, such as kinetochores, 
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centrosomes and the midbody, and this localisation requires the PBD (Elia, Cantley and 
Yaffe, 2003). Phosphorylation of PLK1 at threonine 210 by Aurora A leads to 
enhancement of its catalytic activity (Macůrek et al., 2008; Seki et al., 2008). Once 
PLK1 is activated the PBD specifically recognises phospho-serine/ threonine containing 
peptides. PLK1 binds to proteins that are already phosphorylated on this specific motif, 
allowing subsequent phosphorylation of the target protein at other sites (Elia, Cantley 
and Yaffe, 2003). Some of the PLK1 target substrates are described in Table 1.1. The 
PBD is therefore essential for the specificity of the kinase domain (Lee et al., 1998; Y.-
J. Jang et al., 2002).  
 
Binding of PLK1 to a phospho-epitope shows that priming phosphorylation of a PLK1 
target is a crucial step in the localisation and functions of PLK1. It has been shown that 
this phosphorylated motif can be generated through two mechanisms, either self-
priming by PLK1 or a pro-directed kinase can be the priming factor (Lee et al., 2008). 
A suggestion that PLK1 may be able to carry out self-priming of targets was due to the 
fact that inhibition of the catalytic activity of PLK1 resulted in a loss of localisation of 
PLK1 to centrosomes, kinetochores and midbodies. This showed that the catalytic 
activity of PLK1 was at least in part required for its localisation (Lénárt et al., 2007). 
PLK1 was also shown to phosphorylate PBIP1, a PLK1 kinetochore binding protein, at 
the threonine 78 residue. After this initial phosphorylation, PLK1 bound to this 
phosphorylated threonine motif, ultimately resulting in self recruitment to the 
kinetochore (Kang et al., 2006). Perhaps more commonly, a pro-directed kinase will 
generate the phosphorylated epitope required for PLK1 recruitment and protein 
interaction. Identification of the pro-directed kinases involved in generating this 
phospho-epitope has been attempted, with CDK1 being implicated as one of the main 
pro-directed kinases, and MAP kinases potentially being involved, although less 
frequently (Lowery, Lim and Yaffe, 2005). CDK1 is crucial for the interaction of PLK1  
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Substrate Function 
PBIP1 Centromere component important for proper chromosome segregation 
FoxM1 Transcription factor regulating a number of G2/M specific genes 
CDC25C 
Phosphatase that triggers entry into mitosis by removing the inhibitory 
phosphorylation on Cyclin B/CDK1 
Bub1 Protein kinase with essential roles in the spindle assembly checkpoint 
BubR1 
Protein kinase associated with unattached kinetochores and with roles in 
stabilising kinetochore-microtubule attachments 
PICH 
DNA helicase that is an essential component of the spindle assembly 
checkpoint 
Wee1 Negative regulator of entry into mitosis by inhibiting CDK1 
Myt1 
Negative regulator of entry into mitosis by phosphorylating and 
inactivating CDK1 
Cyclin B1 
Regulatory protein involved in mitosis. Forms a complex with CDK1 
which is then involved in early events of mitosis, such as chromosome 
condensation, nuclear envelope breakdown and spindle pole assembly 
Pericentrin 
Centrosomal protein involved in recruitment of proteins to the 
pericentriolar matrix to ensure proper centrosome and mitotic spindle 
formation 
Nlp 
Centrosomal component involved in regulation of centrosome 
maturation 
MST2 Protein kinase with roles in centrosome disjunction 
Nek9 Protein kinase with roles in centrosome separation 
Ect2 Guanine nucleotide exchange factor required for cytokinesis 
Hbo1 Histone acetylase required for DNA replication licensing 
Orc2 
Component of the origin recognition complex which is required for the 
initiation of DNA replication 
APC/C 
E3 ubiquitin ligase involved in mitotic transition from metaphase to 
anaphase and in promoting mitotic exit and cytokinesis 
 
Table 1.1. List of PLK1 substrates. Some of the PLK1 substrates mentioned in the main text are listed 
in the table. The functions of these PLK1 targets that are relevant to PLK1 are also described. 
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with Forkhead box M1 (FoxM1). CDK1 phosphorylates two key residues in the 
carboxyl terminal domain of FoxM1, which leads to PLK1 interaction with this domain 
(Fu et al., 2008). CDK1 was also shown to phosphorylate hCenexin1 at serine 796 
which resulted in recruitment of PLK1 to this phosphorylated motif and interaction 
between hCenexin1 and the PBD of PLK1 (Soung et al., 2009). Several other PLK1 
targets have also been shown to rely on CDK1 priming of the target for PLK1 
interaction, such as CDC25 (Elia, Cantley and Yaffe, 2003), Bub1 (Qi, Tang and Yu, 
2006) and BubR1 (Elowe et al., 2007). Once the PBD has localised PLK1 to its 
subcellular target, through either mode of priming, the kinase domain can be activated 
to allow PLK1 to carry out its function of phosphorylating one of its numerous 
substrates. 
 
1.2.2. PLK1 Function 
 
PLK1 is a kinase that is essential in cell cycle progression, shown by the evidence that 
inactivating mutations of orthologues of PLK1 result in lethality. This occurs in 
Drosophila, budding yeast and fission yeast. Additionally, a homozygous null PLK1 
mouse is embryonic lethal, failing to proliferate past the eight-cell stage (Lu et al., 
2008). 
 
PLK1 is a mitotic kinase involved in mitotic entry, regulation of the maturation of 
centrosomes, spindle assembly and cytokinesis, as well as having several other 
functions throughout the cell cycle M phase (Barr, Silljé and Nigg, 2004). These 
functions are summarised in Figure 1.2. Numerous substrates of PLK1 have been 
discovered and PLK1 has been shown to localise at many different structures. PLK1 is 
required for almost every step of mitosis, and its cellular localisation changes 
accordingly throughout mitosis. During interphase and prophase, PLK1 is located at the  
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Figure 1.2. The functions of PLK1 during the cell cycle. PLK1 has many roles throughout the cell 
cycle. The most studied functions of PLK1 are in mitosis, where it has been shown to be involved in 
several aspects of mitotic progression, such as mitotic entry, centrosome maturation an separation, spindle 
assembly, APC/C regulation and cytokinesis. PLK1 has also been shown to have roles out with mitosis. 
In interphase it has been suggested that PLK1 is involved in DNA replication. 
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centrosomes, then during prometaphase and metaphase it localises to the kinetochores  
and spindle poles. Throughout anaphase PLK1 localises to the central spindle, and 
finally in telophase PLK1 is found accumulated on the midbody (Schmucker and 
Sumara, 2014). 
 
The first major function of PLK1 is in promoting mitotic entry. To achieve this PLK1 
phosphorylates several proteins to either result in their activation or promote their 
degradation, thus leading to activation of the CDK1/Cyclin B1 complex that is essential 
for mitotic entry. PLK1 phosphorylates CDC25C, an activator of CDK1/Cyclin B1, to 
assist in the promotion of mitotic entry (Toyoshima-Morimoto, Taniguchi and Nishida, 
2002). This activating phosphorylation of CDC25 was initially observed in Xenopus 
with the PLK1 orthologue, Plx1 (Kumagai and Dunphy, 1996). PLK1 also 
phosphorylates Wee1 and Myt1 leading to their degradation (Nakojima et al., 2003; 
Van Vugt, Brás and Medema, 2004; Watanabe et al., 2004). This helps promote mitotic 
entry due to Wee1 and Myt1 having inhibitory functions on CDK1/Cyclin B1. PLK1 
also directly phosphorylates Cyclin B1 at the centrosome, which also assists with the 
entry into mitosis (Toyoshima-Morimoto et al., 2001). Whilst PLK1 has several roles in 
activating CDK1/Cyclin B1, it does not appear to be essential for mitotic entry, as 
inhibiting PLK1 leads to a mitotic arrest, therefore suggesting there is not a block in 
mitotic entry (Steegmaier et al., 2007).  
 
Once entry to mitosis has been achieved, PLK1 is involved in the maturation and 
separation of centrosomes (Lane and Nigg, 1996). Centrosomes are small organelles 
that are the microtubule organising centres in mammalian cells (Bornens, 2012). They 
are composed of a pair of orthogonally arranged centrioles that are surrounded by a 
mass of dense protein, known as the pericentriolar material (Bettencourt-Dias and 
Glover, 2007). The pericentriolar material is composed of proteins such as γ-tubulin, 
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pericentrin and ninein, which are involved in microtubule nucleation and anchoring 
(Doxsey et al., 1994; Bouckson-Castaing et al., 1996). Centrosomes duplicate once per 
cell cycle during S phase, a process that requires CDK2 (Matsumoto, Hayashi and 
Nishida, 1999). Once duplicated, centrosome maturation can occur. Centrosome 
maturation is the process in which the pericentriolar material structurally changes 
during mitosis, by increasing the γ-tubulin ring complexes and recruiting extra 
components (Khodjakov and Rieder, 1999). Centrosome maturation is an important step 
in the centrosome cycle, as the increase in	  γ-tubulin results in an improved capacity of 
the centrosomes to nucleate the microtubules (Moritz et al., 1995; Zheng et al., 1995). 
The role of PLK1 in this process is thought to be through phosphorylation of targets that 
lead to recruitment of γ-tubulin and other proteins that are components of the 
pericentriolar material (Sunkel and Glover, 1988; Lane and Nigg, 1996; Nigg, Blangy 
and Lane, 1996). PLK1 was shown to phosphorylate pericentrin, which may be an 
initiating step in centrosome maturation (Lee and Rhee, 2011). Another centrosome 
associated substrate of PLK1 that has been identified is ninein-like protein (Nlp). Nlp 
has been shown to interact with the	   γ-tubulin ring complexes during interphase, and 
assist in the organisation of microtubules during this stage of the cell cycle. However, in 
mitosis PLK1 phosphorylates Nlp, leading to its displacement from the centrosome. 
This allows the establishment of a mitotic scaffold, possibly due to allowing recruitment 
of further proteins (Casenghi et al., 2003).  
 
After centrosome maturation, the next step in the centrosome cycle is centrosome 
separation. In human cells the separation of centrosomes allows formation of a bipolar 
spindle and is an essential step in mitosis to ensure correct chromosome segregation 
(Meraldi and Nigg, 2002). The process involved in centrosome separation is completed 
in two steps, and PLK1 has been shown to be involved in both of these steps (Smith et 
al., 2011) as summarised in Figure 1.3. The first step is centrosome disjunction. During  
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Figure 1.3. The role of PLK1 in centrosome disjunction and separation. PLK1 is involved in both 
centrosome disjunction and centrosome separation. 1. The centrosomes are joined by the linker of C-
Nap1 and rootletin. 2. A phosphorylation cascade leads to centrosome disjunction. PLK1 phosphorylates 
MST2, which along with hSav1 phosphorylates Nek2A. Nek2A subsequently phosphorylates C-Nap1 and 
rootletin resulting in the removal of the linker. 3. Centrosome separation is powered by the motor protein 
Eg5. PLK1 phosphorylates Nek9, which subsequently phosphorylates Nek6/7, finally resulting in 
phosphorylation and activation of Eg5. Eg5 can then physically drive the centrosomes apart. 
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interphase, the centrosomes are held together by a linker consisting of the proteins C- 
Nap1 and rootletin (Fry et al., 1998; Mayor et al., 2000; Bahe et al., 2005). However,  
once entry into mitosis is achieved, phosphorylation of the linker proteins results in 
their displacement from the centrosomes allowing centrosome disjunction to occur. The 
phosphorylation of C-Nap1 and rootletin is part of a phosphorylation cascade. Nek2A 
phosphorylates C-Nap1 and rootletin (Faragher and Fry, 2003; Bahe et al., 2005), 
however, Nek2A is regulated by MST2 and hSav1, components of the Hippo pathway 
(Mardin et al., 2010). PLK1 was found to phosphorylate MST2, and is therefore an 
upstream activator of centrosome disjunction (Mardin et al., 2011). In parallel to the 
Nek2A pathway, the second step of centrosome separation involves the motor protein 
Eg5 driving the centrosomes apart. Eg5 (also known as kinesin-5 and Kif11) is a 
microtubule-dependent kinesin-like protein, that hydrolyses ATP and converts chemical 
energy into mechanical energy (Zima, 1998). Eg5 is important in generating a bipolar 
spindle and as a result has become a cancer therapeutic target (Sawin et al., 1992; Duhl 
and Renhowe, 2005). PLK1 was shown to be required for Eg5 localisation on the 
centrosome (Smith et al., 2011). Furthermore, Eg5 activity requires phosphorylation. 
CDK1 has been shown to phosphorylate threonine 926 of Eg5 to result in its activation 
(Nigg, Blangy and Lane, 1996; Cahu et al., 2008). However, Nek6/7 also phosphorylate 
Eg5 at another site, serine 1033 (Rapley et al., 2008). Activation of Nek6/7 requires 
phosphorylation by Nek9, which has been shown to be activated by PLK1 (Bertran et 
al., 2011). Overall, PLK1 plays several roles in the centrosome cycle, from maturation 
to both steps of centrosome separation. 
 
As mentioned, PLK1 also localises at the kinetochores during mitosis. The kinetochores 
are the chromosomal structures that the microtubules attach to, and due to this 
localisation of PLK1 it seemed likely that PLK1 may function at the kinetochore 
(Arnaud, Pines and Nigg, 1998). Subsequent studies showed PLK1 was involved in 
	   16	  
microtubule-kinetochore attachments, with depletion of PLK1 leading to a reduction in 
the number of microtubule-kinetochore attachments (Sumara et al., 2004; Lénárt et al., 
2007). One substrate of PLK1 that has been suggested to recruit PLK1 to the 
kinetochore is PBIP1 (Kang et al., 2006). Several others have now also been described 
including Bub1 (Qi, Tang and Yu, 2006) and the outer kinetochore protein NudC 
(Nishino et al., 2006). The functions of PLK1 once at the kinetochore seem to be in 
regards to the spindle assembly checkpoint. Kinetochores that activate the spindle 
assembly checkpoint (kinetochores on chromosomes that are not under tension due to 
incomplete attachments to the microtubules) have high levels of PLK1 (Lénárt et al., 
2007). PLK1 has been shown to phosphorylate proteins that are required for the spindle 
assembly checkpoint, such as Bub1 (Qi, Tang and Yu, 2006), BubR1 (Suijkerbuijk et 
al., 2012) and PICH (Baumann et al., 2007). However, inactivation of PLK1 does not 
prevent the spindle assembly checkpoint from occurring, showing that the 
phosphorylation of the proteins required for the spindle assembly checkpoint by PLK1 
is not an essential step for this checkpoint (Lénárt et al., 2007). The localisation of 
PLK1 at the kinetochores may therefore be for functions in maintaining the 
microtubule-kinetochore attachments. Supporting this idea is the fact that the PLK1 
target, BubR1, is not only required for the spindle assembly checkpoint, but also 
microtubule-kinetochore attachments (Lampson and Kapoor, 2005). 
 
The functions of PLK1 have been greatly studied in early mitosis. However, PLK1 has 
also been implicated in later stages of mitosis, having roles in anaphase promoting 
complex/cyclosome (APC/C) regulation and cytokinesis. APC/C coordinates sister 
chromatid separation and mitotic exit. In the absence of PLK1 function onset of 
anaphase and mitotic exit is impaired, suggesting that PLK1 contributes to APC/C 
regulation (Barr, Silljé and Nigg, 2004). PLK1 has also been suggested to initiate 
cytokinesis by promoting recruitment of the RhoGEF Ect2 to the central spindle. 
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Localisation of Ect2 to the central spindle during anaphase is required to stimulate the 
activation of RhoA GTPase. RhoA GTPase can then assemble and contract the 
contractile ring, to generate a cleavage furrow, which is a requirement of separating the 
two daughter cells (Petronczki et al., 2007). 
 
Out with mitosis, PLK1 has more recently been implicated to have functions in DNA 
replication. An RNAi approach showed that PLK1 is required for DNA replication 
during cell cycle progression as PLK1 depletion resulted in disruption of the pre-
replicative complex formation (Yim and Erikson, 2009). The pre-replicative complex is 
a protein complex that forms at the origin of replication during DNA replication 
initiation. PLK1 was shown to phosphorylate the origin recognition complex 1 (Hbo1), 
which was suggested to be an event required for formation of the pre-replicative 
complex (Wu and Liu, 2008). A further study showed that Orc2 (origin recognition 
complex 2), which is a component of the DNA replication machinery, is a target of 
PLK1 under stressed conditions. PLK1 was shown to phosphorylate Orc2 at serine 188, 
with enhanced phosphorylation occurring when DNA replication was under challenge 
(Song et al., 2011). Additionally, FOR20 (FOP-related protein of 20kDa) was shown to 
be essential for S phase progression and recruitment of PLK1 to the centrosomes. The 
recruitment of PLK1 to the centrosomes was shown to be a crucial step in DNA 
replication. This recruitment by FOR20 may therefore be an intra-S-phase signal that 
maintains proper S phase progression (Shen et al., 2013).  
 
1.2.3. Regulation of PLK1 
 
The levels of PLK1 are required to be tightly regulated during the cell cycle, as 
expression of hyperactive PLK1 can lead to the G2 checkpoint (which is initiated via 
DNA damage and results in G2 arrest) being overridden (Strebhardt and Ullrich, 2006). 
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The activity of PLK1 is regulated in many ways. Golsteyn et al. (1994) showed that the 
levels of PLK1 are low through the G1 and S phases, begin to increase towards the end 
of G2, and finally peak during M phase. In addition, actively proliferating tissues have 
increased levels of PLK1 compared to non-dividing cells (Winkles and Alberts, 2005). 
 
In order for PLK1 to carry out its functions it requires activation. Phosphorylation of 
PLK1 at the conserved threonine residue, 210, located in the T-loop of the kinase 
domain is critical for PLK1 activation (Y. J. Jang et al., 2002). During the G2 phase of 
the cell cycle CDK1 promotes interaction of BORA (an Aurora A co-factor) with the 
kinase domain of PLK1. This causes a conformational change to PLK1 which allows 
Aurora A to phosphorylate PLK1 at threonine 210 resulting in its activation (Hutterer et 
al., 2006; Macůrek et al., 2008; Seki et al., 2008). 
 
At the end of mitosis the PLK1 activity and levels decrease. Upon exit from mitosis the 
anaphase promoting complex/cyclosome (APC/C), an E3 ubiquitin ligase, targets PLK1 
for degradation by the proteasome (Ferris, Maloid and Li, 1998; Lindon and Pines, 
2004). This shows that PLK1 expression is regulated throughout the cell cycle, in a cell 
cycle dependent manner. The factor that controls the cell cycle regulation of PLK1, by 
repressing PLK1 transcription, is the CDE/CHR (cell-cycle dependent element/cell 
cycle gene homology region) element found in the PLK1 promoter (Müller and 
Engeland, 2010). Mutations in this element resulted in a loss of cell cycle specific 
regulation of PLK1 (Uchiumi, Longo and Ferris, 1997). The CDE was first seen in the 
CDC25C promoter (Lucibello et al., 1995). CDC25C, is a cell cycle regulated G2 and 
M phase protein, like PLK1. Further studies then identified that Cyclin A and CDK1 
also contained this CDE repressor element, in addition to a CHR region (Zwicker et al., 
1995).  
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PLK1 expression is also repressed by p53, following DNA damage. It has been 
observed that increased levels of p53, caused by treatment with DNA damage inducing 
agents, leads to decreased levels of PLK1 (McKenzie et al., 2010). The inhibition of 
transcription of PLK1 that results in decreased PLK1 levels can occur via direct binding 
of p53 to the PLK1 promoter. This occurs at two p53 response elements, located at -
2067 to -2016 (p53 responsive element 1) and -816 to -785 (p53 responsive element 2) 
(McKenzie et al., 2010). In addition to a direct p53-dependent repression of PLK1, p53 
also activates its downstream target, p21, which can then bind to the promoter region of 
PLK1, also inhibiting its transcription (Lin et al., 2014). The dimerization partner, RB-
like, E2F and MuvB (DREAM) complex can also repress PLK1 expression by binding 
to the CDE and CHR cell cycle promoter elements. This mechanism of repression is 
dependent on p21 activation by p53 (Fischer et al., 2015).  
 
1.2.4. PLK1 in the DNA Damage Response 
 
There are many sources of DNA damage, both exogenous and endogenous. When a cell 
undergoes DNA damage during interphase, particularly the S or G2 phase of the cell 
cycle, the G2 checkpoint is activated, leading to cell cycle arrest. In this instance PLK1 
is not activated. This occurs due to phosphorylation of Bora at threonine 501 by 
ATM/ATR promoting its degradation by SCF-b-TRCP, an E3 ubiquitin ligase (Qin et 
al., 2013). Without Bora, PLK1 cannot be activated by Aurora A. 
 
In order for cell cycle progression after restoration of DNA damage, PLK1 activation is 
required to recover from the checkpoint arrest (Macůrek et al., 2008). Activated PLK1 
leads to the subsequent activation of CDC25 which eventually results in mitotic entry. 
Claspin, an ATR adaptor protein, is also phosphorylated by PLK1, promoting Claspin 
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degradation. This disturbs the complex of Claspin and ATR, leading to the negative 
regulation of ATR and thus promoting mitotic entry (Mamely et al., 2006). 
 
1.2.5. PLK1 in Cancer 
 
As PLK1 has been linked to proliferation, it is unsurprising that PLK1 has been 
associated with cancer, both in terms of cancer development and cancer progression. 
Elevated PLK1 levels have been shown to be oncogenic and are often correlated with 
poor prognosis (Wolf et al., 1997; W Weichert et al., 2004). Overexpression of PLK1 is 
observed in many human cancers, including non-small cell lung cancer (Wolf et al., 
1997), head and neck squamous cell carcinoma (Knecht et al., 1999), ovarian cancer (W 
Weichert et al., 2004), colorectal cancer (Takahashi et al., 2003; Han et al., 2012), 
breast cancer (Wolf et al., 2000), prostate cancer (Wilko Weichert et al., 2004), gastric 
cancer (Weichert et al., 2006) and melanoma (Strebhardt et al., 2000), as well as several 
others (Tut et al., 2015). It was suggested that increased levels of PLK1 could merely be 
a consequence of increased proliferation in cancer cells and not a driving factor for 
tumorigenesis. Fitting with this idea was the evidence that the PLK1 gene is rarely 
mutated. However, NIH3T3, a normal mouse embryonic fibroblast line, were 
malignantly transformed by transfection and overexpression of PLK1, showing the 
oncogenic potential of PLK1 (Smith et al., 1997). Interestingly, inhibiting the levels of 
PLK1 has been reported to reduce the rate of proliferation in cancer cells, without 
affecting normal cells, therefore it has a great therapeutic potential as a target (Liu, Lei 
and Erikson, 2006). Whilst overexpression of PLK1 appears to be oncogenic, it is very 
rare to see mutations in PLK1. Therefore, the up-regulation of PLK1 may be due to 
upstream proteins involved in its regulation, or epigenetic alterations at the promoter, 
such as DNA methylation of CpG islands (Weng Ng et al., 2016). In addition to a 
seemingly oncogenic role, cancers with elevated PLK1 levels also have a poor patient 
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prognosis and increased risk of metastases (Zhang, Zhang and Kong, 2011; Wang et al., 
2012). 
 
1.2.6. PLK1 Inhibition 
 
PLK1 became a target for cancer therapy in light of its oncogenic role. To begin with, 
different approaches were utilised to determine if inhibiting PLK1 could lead to cancer 
cell death. Initially, anti-PLK1 antibodies were microinjected into Hela cells, which 
showed that cellular proliferation was inhibited via an inability of the cells to complete 
mitosis (Lane and Nigg, 1996). Dominant negative forms of PLK1, single stranded 
DNA antisense oligonucleotides and siRNA targeting PLK1 were all used to confirm 
this initial observation (Cogswell et al., 2000; Spänkuch-Schmitt et al., 2002; Liu and 
Erikson, 2003). In addition to inhibition of cellular proliferation, these studies observed 
apoptosis of cancer cells, whilst these effects were not observed in normal cells. Due to 
the promising findings of inhibiting PLK1 it became a valid reason to develop methods 
of pharmacologically inhibiting PLK1. A number of inhibitors of PLK1 have since been 
developed with a view of blocking PLK1 in cancer cells that express increased levels of 
PLK1.  
 
The small molecule inhibitors of PLK1 that are available either target the kinase domain 
or the PBD. Interestingly, a study comparing the effects of PBD inhibitors with ATP 
competitive inhibitors found that PBD inhibitors resulted in increases in the proportion 
of cells in S and G2/M compared to the control, whereas ATP competitive inhibitors 
only resulted in an increase in cells in G2/M. The PBD inhibitors also resulted in an 
increase in p21 levels and an S phase arrest, suggesting that these inhibitors affected 
interphase cells as well as mitotic cells, whereas the ATP competitive inhibitors 
activated the BubR1 spindle checkpoint kinase, suggesting a mitotic arrest. Overall, this 
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suggested a role for the PBD in S phase whilst the kinase domain was mainly involved 
in mitotic progression (Shin, Woo and Yim, 2015). However, both types of inhibitors 
have shown apoptotic effects in cancer cells and are in preclinical and clinical 
development. 
 
The PBD is an attractive alternative target to the kinase domain. As previously 
mentioned, the PBD has roles in subcellular localisation and target specificity of PLK1. 
Therefore, inhibitors targeting the PBD would interfere with protein interactions that are 
dependent on the PBD, rather than with ATP binding, as is seen in targeting the kinase 
domain (Ravichandran et al., 2011). The first PBD inhibitors described were the natural 
product, thymoquinone, and a synthetic thymoquinone derivative, Poloxin (Reindl et 
al., 2008). Other PBD inhibitors of PLK1 have now been discovered and developed, 
including Poloxin-2 (Scharow et al., 2015), Poloxipan (Reindl et al., 2009) and 
Purpurogallin (Watanabe et al., 2009). However, the inhibitors used in this thesis are 
ATP competitive kinase domain targeted inhibitors, so they will be focused on more 
specifically.  
 
The ATP competitive PLK1 inhibitors targeting the kinase domain have increased 
specificity to PLK1 over other kinases due to certain structural features of PLK1 
(Garuti, Roberti and Bottegoni, 2012). One such feature is the presence of a pocket in 
the hinge region that is created by the Leu132 residue. In other kinases a tyrosine or 
phenylalanine is often found in this place, which may prevent competitive inhibition 
(Ravichandran et al., 2011). Additionally, the ATP pocket comprises a bulky 
phenylalanine at the top, a small cysteine at the base, and an unusually high 
concentration of positively charged residues in the solvent exposed region (Garuti, 
Roberti and Bottegoni, 2012). These features confer specificity for an inhibitor targeting 
	   23	  
PLK1. Numerous inhibitors are available, but the two that have been used in this thesis 
are BI6727 and GSK461364. 
 
BI6727, also known as Volasertib, is a highly potent and selective dihydropteridinone 
derivative PLK1 inhibitor produced by Boehringer Ingelheim (Rudolph et al., 2009). 
BI6727 selectively inhibits PLK1, resulting in G2/M arrest followed by apoptosis in 
cancer cells, whilst in normal cells apoptosis is not observed. This small molecule 
inhibitor therapy results in cell cycle arrest by competitively binding to the ATP binding 
pocket of PLK1. The binding occurs through two hydrogen bonds from the interior of 
the backbone of the amine and carbonyl groups of cysteine 133. This results in BI6727 
blocking the ATP binding site, preventing the catalytic activation of PLK1 (Weiß and 
Efferth, 2012). In initial phase I trials, BI6727 was well tolerated with manageable 
toxicities and antitumour activity in advanced or metastatic solid tumours (Schöffski et 
al., 2012). Further phase I monotherapy trials also showed promising results (C.C. Lin 
et al., 2014; Kobayashi et al., 2015; Nokihara et al., 2015). Phase II trials have had 
mixed results. In a study trial for the treatment of patients with locally advanced 
metastatic urothelial cancer, BI6727 was shown to have an acceptable safety profile, 
however further evaluation as a monotherapy was not warranted due to insufficient 
antitumour activity (Stadler et al., 2014). A second phase II study investigated the 
effects of BI6727 or Pemetrexed as monotherapies or in combination for the treatment 
of non-small-cell lung cancer patients. A lack of efficacy of BI6727 as a monotherapy 
resulted in stopping recruitment of patients to this experimental arm. The combination 
of Pemetrexed with BI6727 compared to Pemetrexed alone did not result in a significant 
increase in toxicity, but also did not improve the efficacy. These findings suggested 
BI6727 was not suitable for treatment of non-smell-cell lung cancer patients (Ellis et al., 
2015).  
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Whilst these two phase II studies did not show promising results for BI6727, a third 
phase II trial showed significantly better outcomes. Acute myeloid leukaemia patients 
were treated with low-dose cytarabine alone or in combination with BI6727. The overall 
outcomes of this trial showed that the combination treatment increased the response rate 
and improved overall survival in acute myeloid leukaemia patients compared to low-
dose cytarabine monotherapy. This was independent of genetic subgroups and although 
the combination treatment resulted in an increased frequency of adverse events, the 
safety profile was considered clinically manageable. This therefore warranted further 
clinical investigation. (Döhner et al., 2014). Further phase I and phase II trials are 
currently on going, with BI6727 being assessed as both a single agent and in 
combination with other agents to treat numerous malignancies.  
 
In 2013 BI6727 received FDA breakthrough therapy designation for treatment of 
patients with acute myeloid leukaemia. The phase III study investigated BI6727 in 
combination with low-dose cytarabine in patients over 65 years of age. This makes 
BI6727 the PLK1 inhibitor that is furthest through the clinical trial pipeline, and the 
lead agent in the PLK1 inhibition field. In 2016 a statement was released from 
Boehringer Ingelheim stating that BI6727 had not met the primary endpoint of objective 
response. Whilst the percentage of patients with objective response was higher in the 
BI6727 and low-dose cytarabine cohort compared to low-dose cytarabine plus placebo 
group, the findings were not significant. This was in part due to severe adverse events 
occurring in the experimental arm (Döhner et al., 2016). With many other trials still 
ongoing, there is still potential for BI6727 in the clinic. Additionally, a recent study 
suggested that combining a proteasome inhibitor with BI6727 leads to enhanced mitotic 
arrest in acute myeloid leukaemia in vitro and prolonged survival of a xenotransplant 
mouse model of human acute myeloid leukaemia in vivo, suggesting that further 
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research into suitable combination treatments could enhance the efficacy of BI6727 
(Schnerch et al., 2017).  
 
GSK461364 is a small molecule PLK1 inhibitor developed by GlaxoSmithKline. In 
vitro studies have shown that GSK461364 has a higher selectivity for PLK1 compared 
to PLK2 and PLK3, than BI6727 (Medema, Lin and Yang, 2011). In preclinical studies 
GSK461364 was found to have increased antiproliferative activity in p53 mutated 
cancers compared to cancers where wild type p53 is retained (Degenhardt et al., 2010). 
This could be a very important finding, as many of the current cancer therapies have 
more successful results in treatment of p53 competent cancers, and p53 is mutated in 
around 50% of cancers. In phase I clinical trials, the pharmacokinetic and 
pharmacodynamics profiles of GSK461364 were assessed in patients with advanced 
solid malignancies. The best response observed was prolonged stable disease for more 
than 16 weeks (Olmos et al., 2011). No further clinical trial studies have been registered 
for GSK461364, however there are many research papers published on this drug. A 
recent study showed that GSK461364 treatment of neuroblastoma cell lines resulted in 
cell cycle arrest and induced apoptosis. Treatment with GSK461364 also delayed 
established xenograft tumour growth in nude mice and increased survival time. This 
suggested that treatment with this drug may benefit neuroblastoma patients with 
elevated PLK1 levels (Pajtler et al., 2017). In osteosarcoma cells GSK461364 was also 
shown to result in a G2/M arrest and cytotoxic effect through the induction of apoptosis 
(Chou et al., 2016). Therefore with future work, GSK461364 may enter further clinical 
trials. 
 
The results of clinical evaluation of PLK1 inhibitors has shown that while they show 
promise in the clinic, improvement is required in decreasing the toxic side effects to 
allow increased doses which may be more successful in targeting cancer cells. 
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1.2.7. PLK1 and p53 
 
As previously mentioned, p53 has been shown to repress PLK1. However, whilst p53 
can repress PLK1, PLK1 has also been reported to repress p53, in a negative feedback 
loop. PLK1 can repress p53 through direct binding. In mammalian cultured cells, PLK1 
was found to physically interact with p53, leading to loss of p53 pro-apoptotic function. 
However, the biological significance of this is uncertain due to this being based on a 
single study (Ando et al., 2004). Indirect mechanisms have also been reported to exist. 
PLK1 was shown to stabilise MDM2, by phosphorylation of serine 260. This promotes 
MDM2 mediated turnover of p53 (Dias et al., 2009). Therefore, it has been shown that a 
negative feedback loop exists between p53 and PLK1, with p53 repressing PLK1 
transcription and PLK1 inhibiting p53 function. This interaction has been represented as 
a schematic in Figure 1.4. The interaction between these two proteins is complex, and 
not fully understood. Numerous studies have been published that research the regulation 
of each protein by the other, either directly or indirectly. However, there is also a lot of 
interest in the correlation between treatment with PLK1 inhibitors and the p53 status of 
cancers. Conflicting reports currently exist in the literature with one study suggesting 
that p53 does not influence the sensitivity of cancer cells to PLK1 inhibition (Sanhaji et 
al., 2012), whilst several other studies show that p53 does alter the sensitivity of cancer 
cells to PLK1 inhibitors (Guan et al., 2005; Liu, Lei and Erikson, 2006; Sur et al., 2009; 
Degenhardt et al., 2010; McKenzie et al., 2010; Danovi et al., 2013; Yim and Erikson, 
2014). To gain a better understanding of p53, an introduction to this highly researched 
protein follows. 
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Figure 1.4. Schematic representation of the interaction between p53, PLK1, MDM2 and p21. 
Studies have reported that p53 and PLK1 are involved in negative regulation of each other. PLK1 was 
shown to directly inhibit p53 function, as well as promote p53 degradation through phosphorylation of 
MDM2. However, p53 has been shown to repress PLK1 expression through both directly binding to the 
PLK1 promoter, and also through activation of p21, which was also shown to inhibit PLK1.  
PLK1% p53%
MDM2%
P
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1.3. p53 
 
1.3.1. Background of p53 
 
The discovery of p53 occurred in 1979, with several independent groups of 
investigators reporting the discovery of an approximately 53kDa protein (Kress et al., 
1979; Lane and Crawford, 1979; Linzer and Levine, 1979; Melero et al., 1979; Smith, 
Smith and Paucha, 1979; Rotter et al., 1980). TP53, the gene encoding the p53 protein 
was initially believed to be an oncogene, due to p53 being discovered as a cellular 
partner of simian virus 40 (SV40) large T-antigen, which is a known oncogene product. 
Observations were also made that transformed cell lines and cells from patient’s 
tumours had elevated p53 levels and p53 was located in the nucleus in transformed 
fibroblasts, but located in the cytoplasm of non-transformed fibroblasts (DeLeo et al., 
1979; Rotter, Abutbul and Ben-Ze’ev, 1983). The first decade of research on p53 
supported the idea that p53 was an oncogene. Several labs cloned p53 and observed that 
transfecting cells with these clones resulted in transformation. It wasn’t until realisation 
that none of the p53 clones being used had the same DNA sequence, that the role of p53 
as an oncogene was questioned. It became apparent that whilst mutated p53 could 
transform cells, wild type p53 could not (Finlay, Hinds and Levine, 1989). This then 
began the era of research of p53 as a tumour suppressor.  
 
Early studies showed that p53 was mutated in several cancers, and now it is known that 
p53 is mutated in approximately 50% of all cancers (Vogelstein, Lane and Levine, 
2000). The main focus of p53 research for many years has been aimed at investigating 
the role of p53 as a tumour suppressor in cancer, due to this p53 was termed the 
‘guardian of the genome’ (Lane, 1992). In the past 38 years, p53 has been extensively 
studied and there is currently more than 86000 publications centred on p53. Although 
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p53 has been shown to be highly important in cancer, there is still no precise answer as 
to how to use this information to treat cancer patients effectively. 
 
1.3.2. Structure of p53 
 
The p53 protein is encoded by the TP53 gene, located on the short arm of chromosome 
17 at position 13.1, and contains 11 exons and 10 introns (Isobe et al., 1986). The 
protein was named on the basis of what was thought to be its molecular mass, as it runs 
at 53 kDa on SDS-PAGE. However, a c-DNA clone of p53 revealed that the protein 
consists of 393 amino acids and has a molecular weight of 43.5 kDa (Harlow et al., 
1985). There are three major functional domains of the protein, the N-terminal 
activation domain (residues 1-93), the DNA binding (core) domain (residues 94-312), 
and the C-terminal regulatory domain (residues 325-393) as shown in Figure 1.5. 
Within the N-terminal domain there are two transcriptional activation (transactivation 
(TAD)) domains and a proline-rich region. The transactivation domain is essential for 
functionality of p53 as a transcription factor (Fields and Jang, 1990; Chang et al., 1995) 
and the proline-rich domain contributes to repression, apoptosis and response to 
ionising irradiation (Walker and Levine, 1996; Venot et al., 1998; Campbell et al., 
2012). The DNA binding core domain is required for sequence specific binding of p53 
to DNA (Kern et al., 1991). The most common mutations in p53 occur in this domain 
and are generally missense mutations. Studies have identified six hotspot mutations in 
the DNA binding domain, residues R175, G245, R248, R249, R273 and R282. These 
mutations result in the loss of function of wild type p53, however, they can also lead to 
gain of novel functions in promoting tumour development (Rivlin et al., 2011). The C-
terminal regulatory domain contains sequences for smaller domains and elements, 
including the nuclear localisation signal, tetramerisation domain, nuclear export signal 
and the regulatory domain. The tetramerisation domain is required for formation of  
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homo- and hetero-tetramers, which are essential for p53 functions in DNA binding, 
protein-protein interactions, transactivation and tumour suppression, as well as p53 
degradation (Chène, 2001). The nuclear export signal has roles in p53 degradation, and 
the nuclear localisation signal is important for p53 localisation into the nucleus. Finally, 
the regulatory domain is regulated by many various post-translational modifications 
including acetylation by p300/CBP and ubiquitylation by MDM2 (Gu and Roeder, 
1997; Rodriguez et al., 2000).  
 
1.3.3. Function of p53 
 
The p53 protein was shown to function as a transcription factor (Raycroft, Wu and 
Lozano, 1990). Numerous further studies have shown that p53 can regulate the 
transcription of a large range of target genes, through sequence specific binding to gene 
promoters containing p53 responsive elements (Kern et al., 1991). The target genes that 
p53 regulates are involved in a wide range of functions which can be grouped into three 
categories: survival, through effects such as cell cycle arrest, senescence, DNA repair, 
autophagy and genome stability; death through apoptosis; and homeostasis, where basal 
levels of p53 are thought to have roles in fertility, metabolism, stem cell differentiation 
and immunity (Meek, 2015). Some of these functions of p53 are represented in Figure 
1.6. 
 
The basal levels of p53 are low, and under unstressed conditions, p53 is a relatively 
unstable protein. However, p53 is activated and stabilised in response to a variety of 
cellular stresses, such as DNA damage, oncogene activation, hypoxia, telomere erosion 
and viral infection. Other sources of stress that activate p53 are represented in Figure 
1.6. Once p53 is activated and the protein levels have stabilised, downstream target 
genes can be stimulated or repressed, dependent on the stress encountered. 
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Figure 1.6. The regulation and functions of p53. Under unstressed conditions, p53 is found at low 
levels in an unstable state. This is in part due to MDM2 mediated degradation. However, upon numerous 
types of cellular stress, with examples found in the orange boxes, the interaction of p53 and MDM2 is 
disrupted, allowing stabilisation of p53. Once stabilised, p53 can carry out one of its many functions, 
which involve activation or repression of genes that are involved in responses such as those indicated in 
the blue boxes.  
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p53 is regarded as a tumour suppressor, and so its overall function is to prevent the 
growth and survival of cancerous cells. Li-Fraumeni syndrome shows the importance of 
p53 as a tumour suppressor as this syndrome presents with the development of multiple 
tumours at a young age, and is as a result of an inherited germline mutation of p53 
(Malkin et al., 1990; Srivastava et al., 1990). Further evidence of the tumour suppressor  
function of p53 is shown by the fact that although p53 null mice develop normally, they 
are highly susceptible to tumour development within 6 months after birth (Donehower 
et al., 1992). 
 
p53 can result in several diverse outcomes for cellular fate. Regulation of the cell cycle 
is one of the most important functions of p53. The cell cycle is regulated by Cyclin 
Dependent Kinases and Cyclins. Activation of p53 can result in cells arresting at several 
different cell cycle checkpoints. To halt the cell cycle, p53 can activate genes that are 
cell cycle inhibitors. For example p53 can transactivate p21, a cyclin-dependent kinase 
inhibitor, which results in cell cycle arrest at the G1/S and G2/M boundaries (El-Deiry 
et al., 1993). Reprimo is another gene stimulated by p53 that inhibits the transition from 
G2 to M (Ohki et al., 2000). Similarly, 14-3-3σ expression is activated by p53, and 
results in a G2 arrest by constraining CDK1 and Cyclin B1 complexes out with the 
nucleus, preventing mitotic entry (Chan et al., 1999; Laronga et al., 2000). The cell 
cycle arrest imposed by p53 can be temporary to allow repair to occur or can be 
permanent resulting in total growth arrest, also known as senescence (Shay, Pereira-
Smith and Wright, 1991). As well as being able to arrest the cell cycle, p53 can also 
promote apoptosis, if the stress or damage is severe and irreparable. The decision to 
undergo apoptosis is also dependent on the cell type, duration of stress and the type and 
level of stress encountered. To do this p53 upregulates genes that are pro-apoptotic (e.g 
BH3 family genes) and downregulates genes that are pro-survival (e.g Bcl-2 family 
genes), to tip the balance towards cell death rather than cell survival (Selvakumaran et 
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al., 1994). Studies have shown that p53 can stimulate the expression of numerous pro-
apoptotic proteins, such as BAX (Toshiyuki and Reed, 1995) and PUMA (Nakano and 
Vousden, 2001). 
 
Prevention of genomic instability is another major function of p53. There is evidence to 
suggest that p53 has roles at the centrosome. Studies have shown that cells lacking p53 
have multiple centrosomes, therefore implicating p53 as having roles in regulating 
centrosome duplication (Fukasawa et al., 1996). If centrosome hyperamplification 
occurs, it can lead to genomic instability as multiple poles can arise, preventing the 
formation of a normal bipolar spindle, which can permit aneuploidy. This effect has also 
been shown in vivo, as a correlation between p53-null mice and centrosome 
hyperamplification and aneuploidy was observed (Fukasawa et al., 1997). Clinical 
implications were also observed as loss of p53 function was associated with increased 
centrosome numbers in breast and head and neck cancers (Carroll et al., 1999). Not only 
does p53 play a role in preventing centrosome hyperamplification, it also acts to prevent 
cells continuing through the cell cycle when centriole duplication fails. A recent study 
showed that depletion of PLK4, which leads to centriole duplication failure, resulted in 
an irreversible cell cycle arrest. However, depletion of p53 in this scenario allowed 
proliferation to continue, with no cell cycle arrest taking place (Lambrus et al., 2015). 
Another study showed that inhibition of centriole duplication led to a G1/S arrest 
through p53 upregulation, which was dependent on p38, a kinase induced by cellular 
stress, rather than ATM, a DNA damage induced kinase (Song et al., 2010). The exact 
mechanism by which p53 may execute such roles is currently unknown. However, p53 
has also been shown to localise to the centrosomes, so direct association with the 
centrosomes may be an important aspect (Morris et al., 2000). One study showed that 
the localisation of p53 at the centrosomes was dependent on phosphorylation of p53 at 
serine 15 by ATM (Tritarelli et al., 2004). As well as roles in regulation of 
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centriole/centrosome duplication, p53 has also been shown to regulate appropriate 
timing of centrosome separation. Cyclin B2 was shown to trigger increased activation of 
Aurora A, which led to upregulation of PLK1. This promoted accelerated centrosome 
separation. However, p53 acted antagonistically to Cyclin B2, to keep Aurora A 
mediated activation of PLK1 in check, which prevented the accelerated centrosome 
separation (Nam and van Deursen, 2014). Clearly there are several potential roles for 
p53 at the centrosomes, which will hopefully be uncovered and underpinned by future 
studies. 
 
Several studies have shown that p53 can prevent karyotypic instability by preventing 
polyploid cells re-entering the cell cycle. Cells that fail to segregate their chromosomes 
correctly often do not complete cytokinesis, which results in cells entering G1 with 4N 
DNA. In p53 competent cells, cells that do not contain the normal 2N DNA 
complement are arrested and fail to continue through the cell cycle. However, cells 
lacking p53 were seen to re-enter S phase with 4N DNA (Cross et al., 1995). It has been 
suggested that p53 is only activated in response to tetraploid cells after mitotic exit. The 
duration of mitotic arrest was indistinguishable between p53 competent and p53 
deficient cells suggesting that p53 does not have a direct role in mitosis. Furthermore, 
p53 competent cells that fail to complete cytokinesis arrest with 4N DNA and lack 
MPM-2 expression (a mitosis specific protein) but express Cyclin E and 
unphosphorylated pRb and have uncondensed chromosomes, suggesting they are 
arrested in a G1 like state (Lanni and Jacks, 1998). Overall, p53 has been implicated to 
function in a post mitotic checkpoint in response to mitotic failure.  It has been 
suggested that p53 is activated in response to mitotic spindle damage through 
interaction with BubR1 leading to increased p53 phosphorylation (Ha et al., 2007).  
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Angiogenesis is an important step in the development of cancer. This is where new 
blood vessels are formed to feed the cancer cells, to allow the tumour to grow. Growth 
factors, such as vascular epithelial growth factor (VEGF) and fibroblast growth factor 
(FGF) have been implicated in this process. However, p53 has been shown to play roles 
in inhibiting this process, adding another aspect of tumour suppressive roles for p53. To 
help in the inhibition of angiogenesis p53 stimulates the expression of natural 
angiogenesis inhibitors, such as alpha collagen (Teodoro et al., 2006) and 
thrombospondin (Dameron et al., 1994).  
 
Invasion and metastases are another two aspects of tumour development. Invasion 
occurs when cancer cells invade neighbouring tissues, and metastasis is the spread of 
cancer cells to another part of the body. The tumour suppressor functions of p53 act to 
inhibit these processes. The p53 dependent upregulation of genes such as MASPIN, can 
help to inhibit metastasis (Zou et al., 2000). 
 
Although much of the research on p53 has been focused in the context of cancer, there 
are a number of other functions for p53 out with this area. Involvement in homeostasis, 
to maintain normal physiological conditions, is another area that p53 has been 
implicated as having a role. Fertility/reproduction can be enhanced in mice by p53 
through the upregulation of leukaemia inhibitory factor. This factor is essential for 
blastocyte implantation (Hu et al., 2007, 2008). Roles for p53 in ageing, metabolism, 
autophagy, glycolysis, differentiation and miRNA processing have also all been shown 
(Vousden and Prives, 2009).  
 
Neurodegenerative diseases have also been linked to p53. The apoptotic functions of 
p53 can lead to neuronal death, thus mediating neurogenerative conditions. In 
Alzheimer’s disease p53 has been implicated to contribute to neuronal death (Culmsee 
and Landshamer, 2006) and in Parkinson’s disease p53 has been shown to lead to 
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dopaminergic neuron death (Qi et al., 2016). Additionally, Huntington’s disease is an 
inherited disorder that ultimately results in the death of brain cells. Mutant forms of 
huntingtin that are the cause of Huntington’s disease activate p53. In mouse models this 
activation of p53 was observed to be involved in the neurodegeneration and 
neurobehavioural abnormalities (Bae et al., 2005). Additionally, p53 was shown to 
induce the expression of huntingtin which was predicted to further disease progression 
(Feng et al., 2006).  
 
1.3.4. Regulation of p53 
 
In unstressed conditions, the levels of p53 are relatively low in the cell. This is due 
negative regulators of p53. One of the best studied and most important regulators of p53 
is MDM2 (murine double minute 2). MDM2 was first identified to interact with p53 in 
1992 (Barak and Oren, 1992; Momand et al., 1992; Oliner et al., 1992). MDM2 is a 
RING-finger E3 ubiquitin ligase that contains a p53 binding domain in its N-terminus. 
This allows specific interaction with p53, resulting in promotion of p53 ubiquitylation 
by the C-terminal RING-finger motif leading to p53 degradation. However, the RING-
finger can also target MDM2 for auto-ubiquitylation and resulting degradation. The 
negative regulation of p53 by MDM2 occurs in an autoregulatory feedback loop. 
MDM2 is a transcriptional target of p53, therefore expression of MDM2 can be 
regulated by the levels of p53, but this results in increased repression of p53 (Wu et al., 
1993). Evidence showing the negative regulation of p53 by MDM2 comes from a study 
that shows MDM2 knockout mice are embryonic lethal, but if p53 is also knocked out 
then the lethality is rescued (Jones et al., 1995; Montes de Oca Luna, Wagner and 
Lozano, 1995). The regulation of p53 is tightly controlled by MDM2, and for p53 
stabilisation to occur the interaction of MDM2 and p53 has to be disturbed. 
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Phosphorylation of p53 is a key event in the disruption of the MDM2-p53 complex. 
Phosphorylation of the serine 15 residue of p53 was reported to result in a 
conformational change in p53 that reduces the ability of MDM2 to bind to p53 (Shieh et 
al., 1997). Phosphorylation of serine 20 was also suggested to be an important event in 
p53 stabilisation. Mutating serine 20 to alanine resulted in a high sensitivity of p53 to 
MDM2 mediated degradation (Chehab et al., 1999; Dumaz et al., 2001). However, 
another study suggested that phosphorylation of threonine 18, and not serine 15 or 
serine 20, was a key event in weakening MDM2 binding affinity for p53 (Schon et al., 
2002). Although, phosphorylation of serine 15 enhances subsequent phosphorylation of 
threonine 18, therefore implicating serine 15 phosphorylation as an important step in the 
disruption of MDM2 and p53 whether directly or indirectly (Dumaz, Milne and Meek, 
1999). Phosphorylation of serine 15 results in stabilisation of p300 and CBP binding to 
p53 (Lambert et al., 1998; Dumaz and Meek, 1999). Due to p300 and CBP having 
transcriptional factor acetyl-transferase activity, p53 is subsequently acetylated at C-
terminal lysine residues 370, 372, 373, 381 and 382. Some of these sites are targets of 
MDM2 ubiquitylation, and as a result acetylation of p53 inhibits ubiquitylation of p53 
by MDM2 (Li et al., 2002). 
 
Numerous different proteins are involved in the activation of p53 depending on the 
cellular stress and the cell type. p53 has been shown to undergo many post-translational 
modifications. It has been shown that the N-terminus of p53 is heavily phosphorylated, 
whilst several C-terminal lysines (as indicated in Figure 1.5) are sites of 
phosphorylation, acetylation, methylation, ubiquitylation, sumoylation and neddylation. 
Several proteins can be responsible for these modifications, such as Chk1, Chk2, ATM, 
ATR, DNA-PK, p38, HIPK2 and JNK, with some of these examples discussed in more 
detail below. These proteins modify p53 on different sites, which is thought to indicate 
the type of stress allowing p53 to carry out the appropriate response. 
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One of the best studied activators of p53 is DNA damage. In response to single or 
double strand breaks p53 is phosphorylated at serine 15, principally by ATM or ATR. 
The phosphorylation of serine 15 is a critical event for transactivation of p53 target 
genes, such as p21 (Loughery et al., 2014), and also leads to subsequent sequential 
modifications of p53 (Sakaguchi et al., 1998). Serine 15 and serine 37 were also shown 
to be phosphorylated by DNA-PK in response to DNA damage (Lees-Miller et al., 
1992). Phosphorylation of serine 20 has also been implicated to have an important role 
in p53 activation. As previously mentioned, the serine 20 residue of p53 is 
phosphorylated by PLK3 upon exposure to hydrogen peroxide (Xie, Wang, et al., 
2001). In addition, whilst ATM and ATR are not directly involved in phosphorylating 
serine 20, in response to DNA damage, the ATM target Chk2 has been shown to 
phosphorylate this site (Hirao, 2000). 
 
UV radiation is another known activator of p53. In this instance, p38, a mitogen-
activated protein kinase (MAPK) has been shown to phosphorylate p53 leading to its 
activation. Studies have shown p38 can phosphorylate serine 33 and serine 46 in 
response to UV radiation (Bulavin, 1999).  
 
This shows that different residues are phosphorylated by different proteins in response 
to different stresses, with all resulting in the stabilisation and activation of p53. Further 
modifications are discussed in detail in several reviews, such as (Appella and Anderson, 
2001).  
 
1.3.5. p53 and cancer 
	  
The role of p53 in cancer has been greatly studied. As one of the most mutated genes in 
cancer, it is unsurprising that p53 has been a key target in cancer research. Many studies 
have focused upon researching the role of mutant p53, and also reactivating p53 as a 
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cancer therapeutic option. It has been shown that loss of p53 function is often a 
requirement for maintaining tumours that are already established. A variety of studies 
showed that by reconstituting p53 in such tumours, tumour regression occurred (Roth et 
al., 1996; Martins, Brown-Swigart and Evan, 2006; Ventura et al., 2007; Feldser et al., 
2010; Junttila et al., 2010; Xue et al., 2011). In the clinic, gene therapy to reintroduce 
p53 through use of vectors, such as adenoviruses, has proved successful in cancer 
treatment (Senzer et al., 2007). Additionally, small molecule drugs that activate and 
stabilise p53 have been developed with the view of enhancing treatment of cancer cells 
that retain wild type p53. In the 50% of tumours carrying wild type p53, often the 
function of p53 is lost due to increased activity of p53 inhibitors, such as MDM2. 
Therefore, pharmacological inhibition of MDM2 also seemed an attractive approach for 
tumours with wild type p53 (Vassilev, 2004). Nutlin-3, an MDM2 inhibitor, has been 
used in many studies to allow p53 activation in cancers (Kojima et al., 2005; 
Sonnemann et al., 2011; Knkele et al., 2012). Other MDM2 inhibitors are also being 
tested for this purpose (Lakoma et al., 2015; Lu et al., 2016). A similar approach of 
reactivation of p53 is also being studied in the context of mutant p53. In these cases, the 
aim of restoration of p53, rather than being through inhibition of negative regulators, is 
to use small molecules to alter the folding of mutant p53 into a wild type conformation 
(Selivanova and Wiman, 2007). 
 
Whilst these approaches show much promise, and enter clinical trials, there are also 
suggestions that in certain cases the presence of wild type p53 in tumours can actually 
have a negative outcome on the response to treatment. Some breast cancers retaining 
wild type p53 were shown to be protected from treatment with some cytotoxic drugs, 
and so in this case p53 was associated with a poor response to treatment (Bertheau et 
al., 2008). Similarly, in certain cases p53 appears to cause a cell cycle arrest upon 
treatment with chemotherapeutic drugs, and results in protection of the cancer cells, 
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whilst p53 defective cells will undergo cell death. One such study showed that reducing 
the levels of the protein kinase ATM increased sensitivity to the poly (ADP-ribose) 
polymerase (PARP) inhibitor, olaparib, in gastric cancer cell lines that were p53 
deficient, either through depletion or inactivation of p53 (Kubota et al., 2014). Another 
study observed a similar effect in mantle cell lymphoma cells, with cells that were ATM 
and p53 deficient also showing increased sensitivity to olaparib (Williamson et al., 
2012). Further work from this group also showed that the ATM and p53 deficient 
sensitivity to olaparib also occurred in colorectal cancer cell lines (Wang et al., 2017), 
showing that this effect was not cancer type specific. Another example of p53 deficient 
cancer cells showing increased sensitivity to chemotherapeutic drugs is in combination 
with checkpoint kinase 1 (Chk1) inhibitors. Use of A-690002 or A-641397, two Chk1 
inhibitors, increased the cytotoxicity of both topoisomerase inhibitors and gamma-
radiation in p53 deficient cells lines, but not p53 expressing cell lines, from different 
tissue origins (Chen et al., 2006). Additionally, another study suggested that a p53 
dependent arrest at G1 may protect cancer cells from undergoing cell death after 
treatment with ionising radiation and Chk1 inhibitors (Petersen et al., 2010). Taking 
advantage of checkpoint defects in p53 deficient cancer cells may be a promising 
strategy for treatment of p53 deficient tumours.  
 
As previously mentioned p53 has also been suggested to impact on the sensitivity of 
PLK1 inhibitors. Using siRNA depletion of PLK1 it was shown that cancer cells 
deficient of p53 showed increased mitotic arrest and aneuploidy and reduced cell 
survival compared to wild type p53 cancer cells (Guan et al., 2005). This was supported 
by similar findings in vitro and in vivo that showed that cancer cells without wild type 
p53 were highly sensitive to PLK1 inhibitors (Sur et al., 2009). Several other studies 
have observed similar effects, with increased sensitivity to PLK1 inhibition being 
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observed in p53 deficient cancers (Liu, Lei and Erikson, 2006; Degenhardt et al., 2010; 
McKenzie et al., 2010; Danovi et al., 2013; Yim and Erikson, 2014). 
 
As mutations in p53 are present in approximately 50% of cancers, and many cancer 
therapeutic options have been suggested to be more effective in p53 wild type tumours, 
the increased sensitivity of p53 deficient cancers to certain treatments, such as PLK1 
inhibitors, could provide an opportunity to treat tumours that do not respond to other 
chemotherapeutics. This may allow an additional treatment plan that could potentially 
enhance the treatment of cancer patients.  
 
1.4. Thesis Aims 
 
As mentioned previously, upon treatment with PLK1 inhibitors there is an apparent p53 
protective effect, with wild type p53 expressing cells showing a reduced sensitivity to 
PLK1 inhibitors in comparison to p53 deficient cells. Several studies have observed 
such findings. However, the mechanism by which p53 exerts such a protective effect is 
currently unknown. There is therefore an unmet need to better characterise this finding 
to allow improved efficacy of PLK1 inhibitors and enhanced treatment options. As a 
result, the aims of this thesis are: 
• To determine whether previous findings of a p53 protective effect upon 
treatment with PLK1 inhibitors can be reproduced. 
• Assuming confirmation of the protective effect, to investigate the underlying 
mechanism(s) and significance of the protective effect of p53 towards PLK1 
inhibitors. 
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Chapter 2 : Materials and Methods  
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2.1. Reagents and Buffers 
 
2.1.1. Antibiotics 
 
Antibiotics Manufacturer 
Working 
Concentration 
Use 
Hygromycin B Life Technologies 400 µg/ml Selection of stable lines 
Geneticin (G418) Life Technologies 400 µg/ml Selection of stable lines 
Ampicillin Melford 100 µg/ml Bacterial selection 
Kanamycin Melford 50 µg/ml Bacterial selection 
 
Table 2.1. List of antibiotics used 
	  
2.1.2. Protein Expression Plasmids 
 
DWM 902 – wild type human p53 open reading frame in pOPRSVICAT 
DWM 903 – wild type human p53 open reading frame, containing serine 15 to alanine 
mutation, in pOPRSVICAT  
DWM 947 – pCMVLacI repressor plasmid   
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2.1.3. Drugs Used in Cell Treatments 
 
All drugs were stored at -20°C. 
 
Drug Manufacturer Catalogue No. Use 
GSK461364 Selleckchem S2193 PLK1 Inhibitor 
BI6727 Selleckchem S2235 PLK1 Inhibitor 
S-Trityl-L-cysteine 
(STLC) 
Sigma 164739 Eg5 Inhibitor 
Etoposide Selleckchem S1225 Topoisomerase II Inhibitor 
Paclitaxel (Taxol) LC Labs P-9600 Microtubule Stabilisation 
Nocodazole Millipore 487928 
Prevents polymerisation of 
microtubules 
IPTG Melford MB1008 Allolactose Molecular Mimic 
KU-55933 Selleckchem S1092 ATM Inhibitor 
VE-821 Selleckchem S8007 ATR Inhibitor 
Z-VAD-FMK Selleckchem S7023 Pan-Caspase Inhibitor 
5-Bromo-2’-
deoxyuridine (BrdU) 
Sigma B9285 Thymidine Analogue 
Nutlin-3 Tocris 3984 
MDM2/p53 Interaction 
Inhibitor 
 
Table 2.2. List of drugs used in mammalian cell treatments. 
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2.1.4. Primary Antibodies 
 
Antibody Manufacturer 
Catalogue 
No. 
Epitope Dilution Species 
Actin Sigma-Aldrich A2066 
Actin carboxy 
terminal (C11 
peptide) 
(Polyclonal) 
1:2000 Rabbit 
BrdU Pure (B44) 
Becton 
Dickinson 
347580 
Ioduridine 
(Monoclonal) 
1:50 Mouse 
BubR1 
Bethyl 
Laboratories 
A300-
386A 
Human BubR1 a.a. 
350-400 
(Polyclonal) 
1:2000 Rabbit 
BubR1 
(Phospho-T680) 
Abcam ab200061 
Human BubR1 a.a. 
650-750 with 
phosphorylated 
T680 residue 
(Monoclonal) 
1:2000 Rabbit 
EG5/KIF11 
Universal 
Biologicals 
A301-076 
Human Eg5 a.a. 
1006-1056 
(Polyclonal) 
1:1000 Rabbit 
Gamma H2A.X  
(Phospho-S139) 
Abcam ab11174 
Human gamma 
H2A.X with 
phosphorylated 
serine 139 residue 
(Polyclonal) 
1:5000 Rabbit 
Gamma Tubulin Sigma-Aldrich T65557 
a.a. 38-53 
(Monoclonal) 
1:1000 Mouse 
GAPDH Sigma-Aldrich G8795 
Rabbit GAPDH 
(Monoclonal) 
1:5000 Mouse 
Histone H3 
(D1H2) 
Cell Signaling 
Technology 
4499 
Human histone H3 
carboxy terminus 
(Monoclonal) 
1:2000 Rabbit 
Histone H3 Millipore 06-570 Human histone H3 1:1000 Rabbit 
	   47	  
(Phospho-S10) with phosphorylated 
serine 10 residue 
(Polyclonal) 
KIF15 
Universal 
Biologicals 
A302-
706A 
Human Kif15 a.a. 
1225-1275 
(Polyclonal) 
1:1000 Rabbit 
MDM2 (4B2) Moravian 4B2 
Human MDM2 
amino terminal 
(Monoclonal) 
1:1000 Mouse 
p21 (H-164) 
Santa Cruz 
Biotechnology 
sc-756 
Human p21 a.a.1-
164 (Polyclonal) 
1:1000 Rabbit 
p53 (DO-1) 
Santa Cruz 
Biotechnology 
sc-126 
Human p53 amino 
terminal, a.a. 11-25 
(Monoclonal) 
1:1000 Mouse 
p53 (Phospho-
S15) 
Cell Signaling 
Technology 
9284 
Human p53 with 
phosphorylated 
serine 15 residue 
(Polyclonal) 
1:1000 Rabbit 
PARP 
Cell Signaling 
Technology 
9542 
PARP caspase 
cleavage site 
(Polyclonal) 
1:1000 Rabbit 
PLK1 (208G4) 
Cell Signaling 
Technology 
4513 
Human PLK1 
carboxy terminus 
(Monoclonal) 
1:1000 Rabbit 
 
Table 2.3. List of primary antibodies used for western blotting, flow cytometry and 
immunofluorescence. 
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2.1.5. Secondary Antibodies 
 
Antibody Manufacturer Catalogue No. Dilution Species 
Mouse IgG (whole 
molecule) – FITC 
Sigma F3008 1:64 Sheep 
Rabbit IgG (whole 
molecule) – FITC 
Sigma F0382 1:80 Goat 
Mouse IgG – HRP Biorad 1721011 1:2000 Goat 
Rabbit IgG – HRP Biorad 1706515 1:2000 Goat 
Mouse IgG (H+L) 
Alexa Fluor® 488 
Life Technologies A11029 1:1000 Goat 
 
Table 2.4. List of secondary antibodies used for western blotting, flow cytometry and 
immunofluorescence. 
	  
	  
	  
2.1.6. Buffers and Solutions 
 
Crystal Violet  
0.4% (w/v) Crystal violet powder 
20% (v/v) Ethanol 
 
Enhanced Chemiluminescence (ECL) Solution 1 
2.5 mM Luminol 
100 mM Tris (pH 8.5) 
396 µM P-Coumaric acid 
 
Enhanced Chemiluminescence (ECL) Solution 2 
0.0192% (v/v) H2O2 
100 mM Tris (pH 8.5) 
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Flow Cytometry Antibody Buffer 
1X PBS 
0.5% (w/v) Bovine serum albumin 
0.5% (v/v) Tween 20 
 
Immunofluorescence Blocking Solution 
1X TBS 
5% (w/v) Bovine serum albumin 
0.1% (v/v) Triton X-100 
 
Phosphate Buffered Saline (PBS) (pH 7.4) 
137 mM Sodium chloride 
10 mM Phosphate 
2.7 mM Potassium chloride 
 
Ponceau S Staining Buffer 
0.2% (w/v) Ponceau S  
5% (v/v) Glacial acetic acid 
 
Propidium Iodide Staining Buffer 
50 µg/ml Propidium iodide  
200 µg/ml RNase A 
1X PBS 
 
Protein Fixative 
10% (v/v) Methanol 
10% (v/v) Acetic acid 
 
SDS Protein Sample Buffer (2X)  
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0.125 M Tris-HCl (pH 6.8) 
20% (v/v) Glycerol 
4% (w/v) SDS 
0.02% (w/v) Bromophenol blue 
 
SDS-PAGE Running Buffer (10X) 
250 mM Tris 
1.92 M Glycine 
1% (w/v) SDS 
 
TAE Buffer (50X) 
2 M Tris 
5.7% (v/v) Glacial acetic acid 
50 mM EDTA (pH 8.0) 
 
Western Blot Blocking Buffer 
1X PBS 
0.1% (v/v) Tween 20 
5% (w/v) Marvel dried milk 
 
Western Blot Transfer Buffer 
25 mM Tris  
192 mM Glycine 
20% (v/v) Methanol 
 
Western Blot Washing Buffer 
1X PBS 
0.1% (v/v) Tween 20 
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2.2. Cell Culture 
 
2.2.1. Maintenance of Cells 
 
All cell lines were cultured at 37°C in a humidified 5% CO2 incubator. Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Gibco) supplemented with 10% (v/v) foetal 
bovine serum (FBS) (Biosera (Labtech International Ltd.)) and 2 mM L-glutamine 
(Gibco) was used to culture all cancer cell lines. When cells reached 70-80% confluency 
they were passaged. Cells were washed twice in PBS, before being detached by 1 ml 
0.5% (w/v) Trypsin (Gibco), a dissociation agent. Cells were then resuspended in 9 ml 
medium and transferred to new flasks (1:10) with additional fresh medium.  
 
 
Cell Line 
ATCC® 
Number 
Tissue and Disease p53 Status Morphology 
HCT116 p53+/+ CCL-247 
Human colorectal 
carcinoma 
p53 wildtype Epithelial 
HCT116 p53-/- 
Vogelstein 
Laboratory 
Human colorectal 
carcinoma 
p53 null Epithelial 
MCF-7 HTB-22 
Human mammary 
gland, breast 
adenocarcinoma 
p53 wildtype Epithelial 
MCF-7 p53 KO 
Buluwela 
Laboratory 
Human mammary 
gland, breast 
adenocarcinoma 
p53 null Epithelial 
U2OS HTB-96 Human osteosarcoma p53 wildtype Epithelial 
H1299 CRL-5803 
Human non-small cell 
lung carcinoma 
p53 null Epithelial 
 
Table 2.5. Mammalian cell lines used. 
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2.2.2. Storage of Cell Lines 
 
All cell lines were stored in freezing medium (FBS + 10% (v/v) DMSO) in liquid 
nitrogen.  Cells were trypsinised and resuspended in medium before being centrifuged 
at 300 RCF for three minutes. The supernatant was then aspirated and the cell pellet was 
resuspended in freezing medium. 1 ml aliquots of the cell suspension were pipetted into 
labelled cryotubes. These were then transported to the -80°C freezer on ice, where they 
were slowly frozen in specialised freezing boxes. After a few days they were 
transported on dry ice to liquid nitrogen. 
 
To bring the cells back into culture, they were quickly thawed at 37°C in a water bath. 
They were then centrifuged gently, the freezing medium was removed and they were 
resuspended in DMEM media before addition to a fresh flask. 
 
2.2.3. Plating Cells for Experiments 
 
Cells to be seeded for experiments were obtained during passaging of cells as described 
above. The resuspended cells were collected and 10 µl of the total 10 ml suspension was 
added to a haemocytometer (Hawksley, 1/400 m2). Cells were counted under the 
microscope and the stock solution of cells was diluted and plated as required for each 
experiment. 
 
2.2.4. MTS Assay 
 
To assess the dose response of different drugs on different cell lines an MTS cell 
viability assay was used. 2500 cells/well were seeded in 96-well plates in triplicate for 
each condition. The following day cells were left untreated, treated with DMSO (vehicle 
control) or treated with 2.5, 5, 10, 20 or 40 nM concentration of GSK461364, BI6727 or 
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Taxol or 0.625, 0.125, 0.25, 0.5, 1 or 2 µM STLC, in a total volume of 100 µl per well. 
After 68 hours of exposure to the drug, 20 µl of CellTiter 96® AQueous One Solution 
Cell Proliferation Assay (MTS) (Promega) reagent was added and the absorbance was 
read 4 hours later (72 hours total treatment) at 560 nM using the GloMax®-Multi 
Detection System (Promega). 
 
2.2.5. Colony Formation Assay 
 
In order to determine the ability of cells to recover post treatment a colony formation 
assay was used. 5x104 cells were seeded in 6-well plates in duplicate. The following day 
cells were treated with a range of concentrations of GSK461364, BI6727 or Taxol for 
72 hours. After treatment, the media was removed and replaced with fresh media. Cells 
were then allowed to grow for a further 10 days, with media being replenished every 2-
3 days. After 10 days the cells were washed twice with 1X PBS, fixed with protein 
fixative, stained with 0.4% crystal violet solution and finally washed 4 times with 
dH2O. Resulting colonies could then be visualised. 
 
2.2.6. Flow Cytometry (S phase labelling) 
 
To allow analysis of differences to the cell cycle distribution upon treatment with drugs, 
flow cytometry was used. 5-bromo-2-deoxyuridine and propidium iodide were used to 
stain the cells to allow determination of the percentage of cells in each stage of the cell 
cycle at the time of harvesting. Cells were seeded in 6 cm plates and treated with the 
desired drug(s). At the treatment end point, cells were labelled with 30 µM BrdU, added 
directly to the media and incubated for 30 minutes. Media was collected, followed by 
washing the cells twice with PBS with each wash being collected also. The cells were 
then trypsinised and pooled together with the supernatant. Cells were then pelleted for 
five minutes at 300 RCF, washed once with PBS, pelleted again then resuspended in 1 
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ml PBS. This suspension was then added to 3 ml of ice-cold ethanol while vortexing to 
prevent clumping of the cells. The cells were then kept at 4°C for at least 30 minutes 
and up to two weeks. 
 
Fixed cells were then subsequently stained. Two washes in PBS-1% FBS were carried 
out, before treatment with 2 M HCl for 20 minutes in a 37°C water bath. During this 
time the cells were gently but effectively shaken. Two washes in PBS-1% FBS then 
followed. The pelleted cells were resuspended in 200 µl of anti-BrdU antibody diluted 1 
in 50 in flow cytometry antibody buffer and incubated for one hour at room temperature 
in the dark. One wash in PBS-1% FBS followed, before resuspension of the cell pellet 
in 200 µl Anti-Mouse IgG (whole molecule)–FITC (Fluorescein isothiocyanate) 
antibody produced in sheep diluted 1 in 64 in flow cytometry antibody buffer. The cells 
were then incubated at room temperature in the dark for 30 minutes. Finally, one more 
wash in PBS-1% FBS was carried out before resuspending the cell pellet in 300 µl of 
propidium iodide staining buffer in FACS tubes (Becton Dickinson). Cells were then 
analysed on the Becton Dickinson FACS Canto Flow Cytometer. Analysis of the data 
was carried out using Flowjo software. 
 
2.2.7. Flow Cytometry (Mitotic cell labelling) 
 
Flow cytometry with propidium iodide alone does not allow discrimination between 
cells in G2 and cells in mitosis. However, use of an antibody detecting a protein that is 
specific to mitosis allows separation of mitotic cells from G2 cells. Histone H3 
phosphorylation at serine 10 is a well established modification that occurs at the onset 
of mitosis, and so use of an antibody to detect this phosphorylation, along with a 
fluorescently tagged secondary antibody, allows quantification of the mitotic index of a 
population of cells through use of flow cytometry. To do this, cells were seeded at the 
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appropriate density in 6 cm dishes, and treated the following day. At the treatment end 
point (4 or 8 hours), the media was collected from the cells and added to a falcon tube. 
The cells were washed twice with PBS, with the washes also being retained, before cells 
were harvested through trypsinisation. Cells were then added to the falcon tube, so that 
both adherent and floating cells could be analysed. After centrifugation at 300 RCF, 
cells were washed once in PBS before fixation in 0.5% (w/v) paraformaldehyde for 20 
minutes at 37°C. Cells were washed once in PBS before resuspension in ice cold 70% 
ethanol and storage at -20°C. Cells were stored for one to three days before staining was 
carried out. 
 
To stain cells, the cells were allowed to warm to room temperature, washed twice with 
PBS–1% FBS, and the resulting pellet was resuspended in 100 µl of flow cytometry 
antibody buffer containing phosphorylated histone H3 (serine 10) at a dilution of 1:100. 
The cells were incubated at room temperature for one hour, before washing in PBS–1% 
FBS, and then a further 30 minutes incubation at room temperature in the dark in flow 
cytometry antibody buffer containing rabbit IgG (whole molecule)–FITC antibody at a 
dilution of 1:80. Cells were washed once again in PBS–1% FBS, before resuspension in 
300 µl of propidium iodide staining buffer in FACS tubes (Becton Dickinson). Cells 
were then analysed on the Becton Dickinson FACS Canto Flow Cytometer and Flowjo 
software was used to analyse the resulting data. 
 
2.2.8. siRNA Transfection 
 
PLK1 and p53 siRNA transfections were performed using a reverse transfection 
procedure. As a control, a non-silencing siRNA was used as a comparison. The siRNAs 
used are described in table 2.6. 1.5 µl of 20 µM siRNA was added to 500 µl Opti-MEM 
I Reduced Serum Media (Gibco) in a 6-well plate. 5 µl of Lipofectamine® RNAiMAX 
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(Invitrogen) was then added, mixed and incubated at room temperature for 20 minutes. 
Cells were trypsinised, counted and diluted to 1x105. Following the 20 minutes 
incubation time 2.5 ml of cells were added to the well (total cell density of 2.5x105 cells 
per well). Cells were incubated for 24 - 48 hours before harvesting/ further treatments 
were carried out.  
Target Sequence Manufacturer 
Catalogue 
No. 
p53 (exon 7) 5’-GACUCCAGUGGUAAUCUACUU-3’ 
Thermo 
Scientific 
OSLR-
001137 
PLK1 
 
5’-GCACAUACCGCCUGAGUCU-3’ 
5’-CCACCAAGGUUUUCGAUUG-3’ 
5’-GCUCUUCAAUGACUCAACA-3’ 
5’-UCUCAAGGCCUCCUAAUAG-3’ 
Thermo 
Scientific 
L-003290-
00 
Non-
silencing 
5’-CAGUCGCGUUUGCGACUGGUU-3’ 
Thermo 
Scientific 
OSLR-
001139 
 
Table 2.6. siRNA used in cell culture. 
	  
2.2.9. Synchronisation by Serum Starvation 
 
Cells were seeded in complete growth media in 6 cm plates and left overnight to adhere. 
The following day, cells were washed three times in PBS before addition of DMEM 
media containing 0.1% (v/v) FBS. Cells were incubated for 24 hours in the reduced 
serum media to synchronise cells in G0. After 24 hours complete growth media was 
added to stimulate synchronous entry of cells back into cycle. Cells were subsequently 
harvested/treated at different time points as described. 
	  
2.2.10. Live Cell Imaging (Phase) 
 
Cells were seeded in 24-well plates to achieve 80% confluency at the time of treatment. 
Desired treatments were added, e.g. GSK461364 or BI6727 and imaging then took 
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place in a heated chamber (37 °C and 5% CO2) using a 10X/03 objective lens on a 
Zeiss Axiovert 200M microscope controlled by Micro-Manager software. Positions 
were selected in each well and after approximately one hour the focus was set. This 
allowed the temperature and CO2 to be maintained, thus ensuring the cells were settled 
to help prevent the focus drifting. Images were taken using a C4742-80-12AG camera 
(Hamamatsu) and were captured every four minutes, with 250 images being recorded 
for each position (approximately 16 hours total time). Image J (National Institutes of 
Health) software was then used to manually calculate the time in mitosis, with the start 
time being the rounding of the cell and the end time being the decision of cellular fate. 
For each condition 50 cells were analysed. 
 
2.2.11. Live Cell Imaging (Fluorescence) 
 
Cells were seeded in µ-slide 8-well chambers (Ibidi) and left overnight to adhere. The 
following day, DMEM media was removed and replaced with carbon dioxide 
independent Leibovitz's L-15 media (Gibco) supplemented with 10% (v/v) FBS, 100 
units/mL of penicillin and 100 µg/mL of streptomycin (Gibco). After approximately 
four hours the L-15 media was removed and 100 nM SiR-DNA (tebu-bio), diluted in L-
15, was added to the cells for 15 minutes. Cells were then washed once with PBS before 
addition of L-15 media containing the drugs of interest. The plate was then mounted on 
the incubated chamber of the Deltavision Elite microscope controlled by SoftWoRx 
software. Cells were imaged using a 40X/1.30NA U Plan FLN oil objective lens with 
images being captured on the CoolSNAP HQ2 camera (Photometrics). The Cy5 channel 
(imaging of far red fluorescence) was used to image the SiR-DNA and a reference 
image in phase contrast allowed the cells to be imaged. Images were taken every 4 
minutes for approximately 250 frames, with 4 optical sections being captured at 5 µm 
optical spacings. Image J software was again used to analyse the duration of mitosis. In 
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this instance the DNA was analysed. The entry to mitosis was determined as the point at 
which the DNA condensed, and the exit from mitosis was the point at which the DNA 
decondensed after chromosome segregation. These times were plotted as box plots to 
allow quantitative differences to be easily observed. 
 
2.2.12. Antibiotic Dose Selection for Stable Lines 
 
In order to determine the concentration of antibiotic required for selection of transfected 
cells, cells were seeded in 24-well plates. Increasing doses of antibiotic (G418 or 
Hygromycin B) were added to the cells in DMEM media, with the range normally being 
0, 200, 400, 600, 800 and 1000 µg/ml. The antibiotic and media were replaced every 2-3 
days. After 1 to 2 weeks of treatment, the lowest concentration of antibiotic that resulted 
in complete cell death was chosen as the required dose for selection. 
 
2.2.13. Production of H1299 p53 S15 and S15A IPTG Inducible Cell Lines 
 
H1299 cells were seeded at a density of 1x106 per 10 cm plate. 1 hour prior to 
transfection cells were washed with 5 ml Opti-MEM, and incubated at 37°C in a further 
5 ml of Opti-MEM. For each plate, 400 µl of Opti-MEM was mixed with the required 
volume of plasmid DNA. 100 ng of each plasmid was used, with DWM 902 or DWM 
903 both being added with DWM 947. A second 400 µl of Opti-MEM was mixed with 
20 µl Lipofectamine® 2000. After five minutes of incubation at room temperature, the 
two solutions were combined and mixed. A further 20 minutes incubation followed 
before adding the transfection mix drop wise to the cells. After approximately six hours 
a further 5 ml of Opti-MEM was added to each plate. The cells were incubated 
overnight, then the following day the media was removed and 10 ml fresh DMEM was 
added to each plate.  
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After a further 24 hours the cells were put into antibiotic selection. Geneticin (G418) 
and Hygromycin B were used at 400 ug/ml concentrations. The selection was 
maintained for two weeks, with renewal of media/ antibiotics every 2-3 days. After two 
weeks colonies were big enough to be seen by eye. The media was removed and the 
plate was washed twice with PBS. A p20 Gilson pipette was then used to pick 
individual colonies. Approximately 10 µl of trypsin was added to each colony and by 
use of scraping and pipetting the colony could be lifted from the plate. The colony was 
then transferred to a 24-well plate with antibiotic selection being maintained. Colonies 
were continually expanded and cells were frozen down for storage and also harvested 
for screening to ensure they were positive for both plasmids. Once positive colonies 
were obtained, the cells could be used for further experiments. 
 
2.2.14. Induction of p53 in H1299 S15 and S15A Inducible Cell Lines 
 
Cells were seeded in 6-well plates or 6 cm dishes. The following day IPTG was added 
to the cells in fresh DMEM media. For testing induction different concentrations of 
IPTG were used, thereafter 100 µM IPTG was used. The IPTG was left for 16 hours 
before harvesting cells or further treatments were carried out, with IPTG being 
maintained throughout the experiments.  
 
2.2.15. Immunofluorescence (Centrosome Staining) 
	  
PLK1 is involved in the maturation and separation of centrosomes, so to investigate 
whether the presence of p53 has an effect on the movement of centrosomes 
immunofluorescence with a gamma-tubulin antibody was used. Cells were seeded on 
poly-L-lysine coated coverslips in 24-well plates. The following day treatments were 
carried out. At the treatment end point cells were washed twice in PBS then fixed on the 
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coverslips using 4% paraformaldehyde solution for 15 minutes. Two washes in PBS 
were then carried out, before addition of 0.1% (v/v) Triton X-100 in PBS for five 
minutes. A further three washes in PBS were completed, then immunofluorescence 
blocking solution was added for 15 minutes at room temperature. Primary antibody (γ-
tubulin) was then diluted in immunofluorescence blocking solution. As a control, 
blocking solution without any antibody was also used. The antibody was then added to 
the coverslips and incubated at room temperature for one hour. Coverslips were then 
washed three times for five minutes each with PBS. Secondary antibody	  (Alexa Fluor® 
488 Goat Anti-Mouse IgG) was then diluted in immunofluorescence blocking solution 
for one hour at room temperature. A further three five minute washes were carried out 
with PBS before staining with DAPI. DAPI was diluted 1:10000 in 
immunofluorescence blocking solution and added to the coverslips for five minutes at 
room temperature. Finally, four washes with PBS were completed and then the 
coverslips were mounted onto slides using	  ProLong® Gold Antifade Mountant (Life 
Technologies). The samples were left to solidify for 24 hours at room temperature and 
then stored at 4°C. The Leica AF6000 wide field fluorescent microscope controlled by 
LAS AF software was used to acquire images using a 63x oil objective and Leica 
DFC420 camera. 
 
2.2.16. Determination of Resistance in Surviving Cells 
 
To address the possibility that the proportion of cells surviving treatment with PLK1 
inhibitors are a resistant population, double treatments were used. Cells were treated for 
72 hours with 5, 7.5, 10, 15 or 20 nM of GSK461364 or BI672. The drug was then 
removed and cells were allowed to recover. Once enough cells were obtained 
(approximately a 70-80% confluent 6 cm plate), the surviving cells were plated for 
further experiments. To determine if the cells were resistant to PLK1 inhibitors MTS 
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and colony formation survival assays were carried out. 2500 cells were seeded per well 
in 96-well plates for the MTS viability assay. Each respective surviving concentration 
was plated along with cells that had never been exposed to PLK1 inhibitors as a control. 
The day after seeding, cells were treated with increasing doses of the respective PLK1 
inhibitor (0, 2.5, 5, 10, 20, 40 or 80 nM), and incubated for 68 hours before addition of 
MTS reagent for a further four hours. The absorbance was then determined at 560 nm 
using the GloMax®-Multi Detection System (Promega). For the colony formation assay 
cells were seeded in 6-well plates, treated with a range of concentrations of PLK1 
inhibitors and incubated for 72 hours. The drug was then removed and cells were 
allowed to recover in fresh media. After 10-12 days the cells were stained with crystal 
violet and resulting colonies were visualised.  
 
2.3. Protein Biology Techniques 
 
2.3.1. Preparation of Samples for SDS-PAGE and Western Blotting 
 
In order to determine differences in protein levels western blotting was used. Cells were 
seeded in 6-well or 6 cm plates and treatments were carried out as indicated in the figure 
legends. At the treatment end point the cells were placed on ice. The media was 
collected in order to retain floating cells, which could be apoptotic or mitotic cells, and 
this was centrifuged at 300 RCF for five minutes at 4°C. 1 ml of 1X PBS was added to 
the well/plate containing the adherent cells. A cell scraper was used to remove cells 
from the plate and put them into suspension. This suspension was transferred to a 
microcentrifuge tube and kept on ice. The supernatant from the pellet of floating cells 
was aspirated then the pellet was resuspended in 100 µl of PBS and transferred to the 
microcentrifuge tube containing the equivalent sample of adherent cells. This was 
centrifuged at 10000 RCF for five minutes at 4°C, before washing in 1X PBS. The 
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supernatant was then aspirated and the pellet was lysed. 250-400 µl (depending on pellet 
size) of 2X SDS protein sample buffer was added to lyse the pellet, with a 15 minute 
incubation period on ice following. The sample was then sonicated for 20 seconds at 
30% amplitude, before centrifugation at 10000 RCF for five minutes. The Bio-Rad DC 
Protein Assay was used to quantify the protein concentration with absorbance being 
measured using the GloMax®-Multi Detection System (Promega). The sample was then 
diluted in 2X SDS protein sample buffer to give a concentration of 1 µg/µl and DTT 
was added to a final concentration of 0.1 M. Samples were then boiled for five minutes 
at 100°C, centrifuged and were then ready to load onto gels as described below. 
 
2.3.2. SDS-PAGE 
 
To separate proteins SDS-PAGE was used with either 8% or 10% polyacrylamide gels, 
dependent on the molecular weight of the protein of interest. Both 8% and 10% 
resolving gels comprised 382 mM Tris (pH 8.8), 0.1% (v/v) SDS, 0.1% (v/v) APS and 1 
µl/ml N,N,N,N’-Tetramethylethylenediamine (T.E.M.E.D.). Only the acrylamide 
concentration differed between the 8% and 10% gels with acrylamide being added at the 
desired concentration from a 30% (w/v) acrylamide stock (Severn Biotech Ltd.). The 
resolving gel was poured first, leaving enough space for the well comb to be inserted 
later. This gap was filled with 70% (v/v) ethanol, to remove any bubbles whilst the gel 
set. After waiting at least 10 minutes to allow the gel to set, the ethanol was poured off, 
and the stacking gel was added. The stacking gel was composed of 4.9% (v/v) 
acrylamide, 123 mM Tris (pH 6.8), 0.1% (v/v) SDS, 0.1% (v/v) APS and 1.63 µl/ml 
T.E.M.E.D. As soon as the stacking gel was poured, a well comb was added to create 
the wells required for addition of samples. Once set, the gels were inserted into a 
vertical slab electrophoresis chamber (Atto) with 1X SDS-PAGE Running Buffer. 20 µg 
of protein sample was loaded onto the gel, along with 4 µg of PageRuler™ Prestained 
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Protein Ladder (ThermoFisher Scientific). The gel was then run at 100 V until the dye 
front reached the bottom of the gel. 
 
2.3.3. Western Blotting 
 
To transfer the proteins separated by SDS-PAGE, western blotting was used. The gel 
was put into a ‘sandwich’ with Whatman filter paper (Fisher Scientific), sponges and 
Hybond ECL nitrocellulose membrane (GE Healthcare). Transfer was then carried out 
in a Mini Trans-Blot® Cell (Bio-Rad) with western blot transfer buffer for one hour at 
100 V. The membrane was then stained with Ponceau S staining buffer to detect the 
presence of proteins on the membrane. After rinsing with water, the membrane was 
blocked on a roller for one hour at room temperature in western blot blocking buffer. 
Primary antibody was then added to Western blot blocking buffer at the dilution 
indicated in table 2.3 before addition to the membrane and overnight incubation at 4°C 
on a roller. 
 
The following morning the membrane was washed three times at five minutes each in 
PBST then the appropriate secondary antibody (either mouse or rabbit horseradish 
peroxidase-conjugated secondary antibody) was added to the membrane in blocking 
buffer and incubated for one hour at room temperature. A further three five minute 
washes were carried out before addition of enhanced chemilluminescence reagent 1 and 
reagent 2, mixed in a 1:1 ratio, to allow complete and even coverage of the membrane. 
The ChemiDoc™ MP Imaging System (Bio-Rad) controlled by Image Lab 4.1 software 
was then used to visualise the membrane. 
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2.4. Molecular Biology Techniques 
 
2.4.1. Transformation of Bacteria 
 
Competent E.coli bacteria (DH5α) were used for transformation of plasmid DNA into 
bacterial cells. A frozen aliquot of DH5α was allowed to thaw on ice. 100 µl of DH5α 
competent cells were added to 0.5 µg of plasmid DNA in a microcentrifuge tube. Gentle 
tapping was used to mix the solution of DNA and bacteria, before incubation on ice for 
approximately 12 minutes. The bacteria were then heat shocked at 37°C in a water bath 
for five minutes. The tube was then put on ice again, before addition of 1 ml of LB 
containing the appropriate antibiotic. The mixture was then incubated at 37°C for one 
hour on a shaker. LB agar plates containing the appropriate antibiotic (ampicillin or 
kanamycin) were prepared. After one hour of incubation, 100 µl of the transformation 
mixture was spread evenly over the agar plate. The plate was then incubated overnight 
at 37°C in an inverted position and the following morning the plate was checked for 
colonies. A colony could then be picked and added to LB for overnight growth at 37°C, 
or the plate could be stored at 4°C. 
 
2.4.2. Glycerol Stocks 
 
Plasmids were stored as bacterial glycerol stocks at -80°C. After transformation of 
plasmid DNA in competent bacterial cells (described above) the transformed bacteria 
were grown overnight in 4 ml LB, including the appropriate antibiotic, at 37°C with 
shaking. The following morning, 800 µl of the suspension was added to 300 µl 100% 
glycerol in a cryotube. The mixture was then snap frozen on dry ice before long term 
storage at -80°C. 
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2.4.3. Obtaining Plasmid DNA from Glycerol Stocks 
 
Depending on the amount of plasmid required, a small or large culture could be grown. 
In the case of a small culture, 4 µl of antibiotic was added to 4 ml LB, and for a large 
culture 400 µl of antibiotic was added to 400 ml LB. A stab was taken from the glycerol 
stock and added to the LB. The bacteria were then grown overnight at 37°C with 
agitation. If a small culture was used, 1.5 ml of the solution was added to a 
microcentrifuge tube. The solution was then centrifuged, and the plasmid DNA was 
recovered using the QIAprep Spin Miniprep Kit (Qiagen), carried out as described by 
the manufacturer’s instructions. If a large culture was used, all of the bacterial solution 
was pelleted. The supernatant was then poured off and the resulting pellet was used for 
recovery of the plasmid DNA by following the manufacturer’s instructions on the 
QIAprep Spin Maxiprep Kit (Qiagen). Following completion of the maxi or mini prep 
kit, the concentration of the resulting plasmid DNA could be measured using a 
NanoDrop. 
 
2.4.4. Agarose gel electrophoresis 
 
In order to separate DNA obtained from maxi or mini preps, agarose gel electrophoresis 
was used. A 1% agarose gel was made with 1X TAE buffer, and 0.5 µg/ml ethidium 
bromide. The ethidium bromide allowed visualisation of DNA, through its intercalation 
to DNA and its fluorescent properties. Once the gel had set, it was assembled in a 
horizontal running chamber (Atto), and submerged in 1X TAE buffer. DNA loading 
buffer was then added to the DNA samples and loaded to the gel, along with DNA 
ladder, before running at 100V. Once the gel had successfully run, the gel was removed 
from the chamber and the ChemiDoc™ MP Imaging System (Bio-Rad) controlled by 
Image Lab 4.1 software was used to visualise the gel. 
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Chapter 3 : p53 reduces sensitivity to PLK1 
inhibitors  
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3.1. Background 
 
Previous work in the Meek lab has shown that p53 has a substantial effect on the levels 
of PLK1 (McKenzie et al., 2010) and some reports suggest that in the absence of p53, 
levels of PLK1 increase (Sur et al., 2009). Using PLK1 knockdowns Guan et al. (2005) 
showed that mitotic arrest and apoptosis was enhanced in cancer cells with defective 
p53.  Further reports have also suggested that p53 can have a negative influence on the 
outcome of treatment with PLK1 inhibitors (Liu, Lei and Erikson, 2006; Sur et al., 
2009; Degenhardt et al., 2010; McKenzie et al., 2010; Danovi et al., 2013; Yim and 
Erikson, 2014).  As p53 is lost or mutated in around 50% of cancers, and thus 50% of 
cancers retain wild type p53, it is of great importance to know if p53 has an effect. If 
use of PLK1 inhibitors will only be beneficial to cancers that have either lost p53 or 
have a mutation in p53, then the p53 status of the cancer should first be assessed before 
treatment commences. Therefore, this chapter aims to confirm whether p53 plays a role 
in influencing the resistance to PLK1 inhibition as a cancer therapeutic treatment. 
 
In this chapter, established cells lines were used to investigate the impact of p53 upon 
treatment with PLK1 inhibitors. This included the HCT116 cell line, which is a colon 
cancer-derived cell line that expresses wild type p53. However, an isogenic line in 
which full-length p53 has been removed through targeted homologous recombination 
was also used (Bunz et al., 1998). This provides a highly useful tool for assessing the 
roles of p53, as the only difference between these lines is the p53 status. 
 
3.2. Aim 
 
The aim of this chapter is to determine whether p53 offers a protective effect upon 
treatment with PLK1 inhibitors. 
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3.3. Results 
	  
3.3.1 p53 increases resistance to treatment with PLK1 inhibitors 
	  
As previously discussed, there has been much debate about the involvement of p53 in 
the outcome of treatment with PLK1 inhibitors. The first starting point was therefore to 
test whether p53 has a role on the efficacy of PLK1 inhibitors. In order to address the 
question of whether p53 offers a protective effect upon treatment with PLK1 inhibitors, 
two independent PLK1 inhibitors developed by GlaxoSmithKline and Boehringer 
Ingelheim, GSK461364 and BI6727 respectively, were used. Use of two independently 
developed inhibitors targeting the same protein reduces the risk that observed results are 
due to off target effects. Two approaches of determining cell survival were used: a 
short-term MTS assay and a longer-term colony formation assay. The MTS assay, a 
colorimetric assay based on the reduction of MTS tetrazolium by viable cells to form a 
coloured formazan, with the resulting absorbance being read, was used with different 
doses of PLK1 inhibitors (0-40 nM). The HCT116 parental line (p53+/+), and a 
derivative line lacking full-length p53 expression (p53-/-) were seeded in 96-well plates 
in triplicate for each condition tested. As can be seen in Figure 3.1 both drugs reduced 
cell viability in a dose dependent fashion. However, the wild type p53 cells have 
increased resistance to both PLK1 inhibitors compared to the p53-/- cells, suggesting 
wild type p53 is contributing to the efficacy of these inhibitors. This is consistent with 
previous studies that suggest that p53 provides a protective effect upon inhibition of 
PLK1 (Guan et al., 2005; Liu, Lei and Erikson, 2006; Sur et al., 2009; Degenhardt et 
al., 2010; McKenzie et al., 2010; Danovi et al., 2013; Yim and Erikson, 2014).  
 
The colony formation recovery assay also used different doses of PLK1 inhibitors, with 
72 hours of treatment, followed by removal of the drug and an additional 10 days of 
recovery in fresh media. The resulting colonies were fixed and then stained with crystal 
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violet to allow visual representation of the survival. As can be seen in Figure 3.2 the 
cells were killed in a dose dependent manner, reflecting the results of the MTS assay. 
Again, when treated for 72 hours the p53+/+ cells showed increased recovery compared 
to the p53-/- cells, supporting the results of the MTS viability assay.  
 
One possibility of the p53 protective effect was that any form of inhibition of mitosis, 
not specifically PLK1, would result in this outcome. In order to address this Taxol, a 
microtubule poison that prevents the depolymerisation of microtubules resulting in a 
mitotic arrest at the metaphase/anaphase boundary, was used in both the MTS and 
colony formation assays with the HCT116 lines. Figure 3.3 shows that in the case of 
Taxol, absence of p53 does not increase sensitivity in the MTS assay. In the colony 
formation assay there is a slight increase in the number of surviving cells in the 
HCT116 p53-/- cell line compared to the p53+/+ cell line. This is not the same as 
observed with PLK1 inhibitors. Overall, this suggested that the p53 protective effect 
was a consequence of a PLK1 targeted mitotic arrest rather than a general mitotic arrest.  
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Figure 3.1. Cells expressing wild type p53 show reduced sensitivity to the independently developed 
PLK1 inhibitors, GSK461364 and BI6727. HCT116 p53+/+ and p53-/- cells were treated for 72 hours 
with increasing concentrations of the PLK1 inhibitor compounds, GSK461364 (A) or BI6727 (B). Cell 
viability was then measured using an MTS assay. A Student’s t-test was used to evaluate significance of 
survival between p53+/+ and p53-/- cells at each concentration of PLK1 inhibitor. Experiments were 
performed with five biological replicates and three technical replicates. *p<0.05; **p<0.01;***p<0.001. 
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Figure 3.2. HCT116 p53+/+ and p53-/- cells treated with PLK1 inhibitors. HCT116 p53+/+ and p53-
/- cells were treated with increasing doses of PLK1 inhibitors GSK461364 (A) or BI6727 (B) for 72 
hours. The drug was then removed and the cells were allowed to recover in fresh media for a further 10 
days. Cells were then washed in PBS, fixed in protein fixative and stained with crystal violet. The data are 
representative of three independent experiments each conducted in duplicate. 
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Figure 3.3. The outcomes of treatment of cells with Taxol is independent of the presence of p53. (A) 
HCT116 p53+/+ and p53-/- cells were treated for 72 h with DMSO, 2.5, 5, 10, 20 or 40 nM Taxol. Cell 
viability was then measured using an MTS assay. The data are representative of three independent 
experiments each conducted in triplicate. (B) HCT116 p53+/+ or p53-/- cells were treated for 72 h with 
increasing concentrations of Taxol. Following removal of the drug, cells were grown for a further 10 
days. Surviving cells/colonies were detected following removal of the medium, fixing of the cells and 
staining with crystal violet. The data are representative of three independent experiments. 
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3.3.2 Cells surviving treatment with PLK1 inhibitors are not a resistant 
population 
 
The appearance of cells that survive treatment with GSK461364 and BI6727 could 
indicate that there is a resistant population of cells within the HCT116 line, giving rise 
to the surviving colonies. In order to address this possibility the surviving cells were 
tested for resistance. To do this HCT116 p53+/+ and p53-/- cells were treated with 5, 
7.5, 10, 15 or 20 nM of GSK461364 for 72 hours. The drug was then washed off and 
the cells were allowed to recover in fresh media. Once the surviving cells were around 
70 - 80% confluent, they were pooled and expanded into a 6 cm dish to allow enough 
cells to set up further experiments. When enough cells were obtained they were 
collected and counted. These cells were then plated for MTS and colony formation 
assays. As a control, parental HCT116 p53+/+ and p53-/- cells that had not been 
exposed to any PLK1 inhibitor were also plated. It was expected that if resistant 
populations existed then cells surviving and recovering from treatment with a particular 
concentration of PLK1 inhibitor would then survive the second round of treatment at the 
same dose.  
 
For the MTS assay, 2500 cells were seeded per well in 96-well plates. The HCT116 
p53+/+ and p53-/- parental cells, and cells surviving 5, 7.5, 10, 15 and 20 nM treatments 
of GSK461364 were seeded in triplicate. These cells were then treated with DMSO or 
treated with 2.5, 5, 10, 20, 40 or 80 nM of GSK461364. The viability of cells after 
exposure to the drug for 72 hours was then measured. The resulting graphs are shown in 
Figure 3.4 A and C. As can be seen, there was very little difference between the 
different populations of cells, with no increase in resistance of cells that had previously 
been treated. This suggested that there is not a resistant population of cells within the 
HCT116 p53+/+ or p53-/- line. 
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Next the colony formation assay was used. Again the same populations of cells were 
seeded in 6-well plates, and then treated with DMSO, 5, 7.5, 10, 15 or 20 nM of 
GSK461364. The cells were exposed to the drug for 72 hours before being allowed to 
recover in fresh media for a further 10 days. Figure 3.4 B and D show that there is not a 
significant increase in surviving cells in the populations that have previously survived 
GSK461364 treatment. This fits with the results of the MTS assay, in suggesting that 
the colony formation assay has not selected for the survival of a resistant population of 
cells.  
 
Next, the same procedure was carried out using BI6727. HCT116 p53+/+ and p53-/-
cells were treated in the same manner as above, but with BI6727 replacing GSK461364 
at each stage. Again, MTS and colony formation assays and were used for the cells 
recovering from each concentration of BI6727. As can be seen in Figure 3.5 the cells 
recovering from treatment showed no obvious difference in sensitivity to BI6727 
compared to cells that had never been treated in both the MTS and colony formation 
assays. This suggests that HCT116 p53+/+ and p53-/- cells surviving either GSK461364 
or BI6727 are not a resistant sub population of cells within the culture and this is 
irrespective of the p53 status. 
 
To further enhance this experiment, U2OS cells were then treated in the same way to 
determine the outcome in a different cellular background. First the U2OS cells were 
treated with 5, 7.5, 10, 15 or 20 nM GSK461364 or 5, 7.5, 10 or 15 nM BI6727. The 
cells surviving treatment were then plated for an MTS assay. Little differences were 
observed between U2OS cells that had never been exposed to PLK1 inhibitors and the 
cells that had survived treatment as shown in Figure 3.6. Again this supported the result 
that there is not a population of cells within the culture that are resistant to PLK1 
inhibitors and potentially providing surviving cells. 
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Figure 3.4. Cells surviving treatment with GSK461364 are not a result of a resistant population of 
cells. HCT116 p53+/+ and p53-/- cells were treated with 5, 7.5, 10, 15 or 20 nM GSK461364 for 72 
hours. The drug was then removed and the surviving cells were allowed to recover. When enough cells 
were obtained they were plated for further experiments along with the parental HCT116 p53+/+ and p53-
/- cells that had not been exposed to GSK461364. For MTS assays cells were plated and subsequently 
treated with 2.5, 5, 10, 20, 40 or 80 nM GSK461364 for a further 72 hours. The resulting survival is 
shown for HCT116 p53+/+ (A) and p53-/- (C) populations. The graphs are representative of this 
procedure being carried out twice and each time samples being tested in triplicate. For colony formation 
assays cells were plated and treated for 72 hours with DMSO, 5, 7.5, 10, 15 or 20 nM GSK461364. The 
drug was then removed and the cells were allowed to recover in fresh media for a further 10 days before 
fixing and staining with crystal violet. Survival of HCT116 p53+/+ (B) and p53-/- (D) cells is shown. 
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Figure 3.5. Cells surviving treatment with BI6727 are not a result of a resistant population of cells. 
HCT116 p53+/+ and p53-/- cells were treated with 5, 7.5, 10, 15 or 20 nM BI6727 for 72 hours. The drug 
was then removed and the surviving cells were allowed to recover. When enough cells were obtained they 
were plated for further experiments along with the parental HCT116 p53+/+ and p53-/- cells that had not 
been exposed to BI6727. For MTS assays cells were plated and subsequently treated with 2.5, 5, 10, 20, 
40 or 80 nM BI6727 for a further 72 hours. The resulting survival is shown for HCT116 p53+/+ (A) and 
p53-/- (C) populations. The graphs are representative of this procedure being carried out twice and each 
time samples being tested in triplicate. For colony formation assays cells were plated and treated for 72 
hours with DMSO, 5, 7.5, 10, 15 or 20 nM BI6727. The drug was then removed and the cells were 
allowed to recover in fresh media for a further 10 days before fixing and staining with crystal violet. 
Survival of HCT116 p53+/+ (B) and p53-/- (D) cells is shown. 
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Figure 3.6. U2OS cells surviving treatment with GSK461364 or BI6727 are not a result of a 
resistant population of cells. U2OS cells were treated with 5, 7.5, 10, 15 or 20 nM GSK461364 or 5, 
7.5, 10 or 15 nM BI6727 for 72 hours. The drug was then removed and the surviving cells were allowed 
to recover. When enough cells were obtained they were plated for MTS assays along with parental U2OS 
cells that had not been exposed to PLK1 inhibitors. Plated cells were subsequently treated with 2.5, 5, 10, 
20, 40 or 80 nM GSK461364 (A) or BI6727 (B) for a further 72 hours. Cell survival was then determined 
by a MTS assay. The graphs are representative of this procedure being carried out twice and each time 
samples being tested in triplicate. 
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3.4. Discussion 
	  
The findings of this chapter support previous observations that p53 reduces sensitivity 
to PLK1 inhibitors (Guan et al., 2005; Liu, Lei and Erikson, 2006; Sur et al., 2009; 
Degenhardt et al., 2010; McKenzie et al., 2010; Danovi et al., 2013; Yim and Erikson, 
2014). By using the HCT116 isogenic lines, the effect of p53 could be focused upon, as 
the p53 status is the only difference between these lines. Both a short term survival 
assay and longer term recovery assay had similar findings in regards to the p53 status. 
Additionally, further experiments showed that the surviving colonies were not a 
selection of resistant clones in the population, therefore the protective effect of p53 
must occur through an innate mechanism. Interestingly, the effects of Taxol were p53 
independent in these assays. This suggested that p53 does not have the ability to alter 
sensitivity to all mitotic inhibitors. Previous studies have shown that the sensitivity of 
different cancer cells and patient responses to Taxol are independent of p53, supporting 
the findings in this thesis (Debernardis et al., 1997; Rantanen et al., 2002; Reinecke et 
al., 2005; Sezgin et al., 2005).  
 
There is evidence to suggest that PLK1 upregulation in cancer is associated with 
mutations in p53 (King et al., 2012; Watanabe et al., 2015), and the clinical outcome for 
these patients is poorer than cancers expressing PLK1 or TP53 mutations alone (King et 
al., 2012). This would imply that treatment of patients that express PLK1 and lack 
functional p53 may be ideal candidates for treatment with PLK1 inhibitors. Whilst 
numerous clinical trials have been carried out using PLK1 inhibitors, and the patient 
response varies considerably within each study, to date, these trials have not 
investigated whether the p53 status of patients could be a reason for the differences in 
response to PLK1 inhibitors. This would be an interesting study to conduct in the future 
and could enhance the clinical efficacy of PLK1 inhibitors by targeting patients most 
likely to respond to this type of treatment. 
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Chapter 4 : PLK1 inhibitors lead to induction of 
p53 through the DNA damage response pathways 
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4.1. Background 
	  
It has been shown in chapter 3, and by others, that the presence of p53 results in a 
protective effect when PLK1 inhibitors are applied. However, it has not been shown 
how this may occur. Previous studies have shown that PLK1 inhibitors lead to an arrest 
in early mitosis, at the prometaphase stage. Upon treatment with PLK1 inhibitors, cells 
generally accumulate in mitosis with monopolar spindles, due to a failure in centrosome 
separation. This forms the classic ‘polo’ effect of the condensed chromosomes. Some 
studies have suggested that inhibition of PLK1 can also lead to an intra-S-phase arrest 
(Mandal and Strebhardt, 2013). Additionally, inhibition of PLK1 has been shown to 
result in DNA damage and apoptosis. However, how these observations link to p53 and 
the p53 status of cancer cells is an area of research that is currently uncovered. 
 
One of the classic activators of p53 is DNA damage. Upon DNA damage, p53 is 
phosphorylated by ATM and ATR at serine 15. This phosphorylation is critical for p53 
activation and function in transactivating downstream targets, such as p21 (Loughery et 
al., 2014). The functional effects of activated p53 can vary depending on the input stress 
type and strength. In general, there are two outcomes, cell cycle arrest (either temporary 
to allow repair to occur or a permanent total growth arrest) or cell death (generally 
through apoptosis). Therefore, p53 can have dramatic effects on the cell cycle. Flow 
cytometry is a useful technique that can be used to assess the cell cycle distribution of a 
population of cells, allowing cell cycle arrests to be observed. This technique is 
therefore highly useful for investigating p53 dependent effects. 
 
It is well established that p53 responds to failed mitoses. When a cell enters G1 with an 
abnormal DNA complement, due to mitotic failure, p53 facilitates cell cycle arrest or 
apoptotic cell death to prevent genomic instability. Additionally, if DNA damage occurs 
during mitosis, it has been suggested that p53 is alerted to this damage upon mitotic exit 
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(Hayashi and Karlseder, 2013). During mitosis the DNA damage response is limited. It 
has been suggested that a prolonged mitotic arrest can lead to the formation of DNA 
damage foci at the telomeres. This DNA damage response at the telomeres is thought to 
be caspase dependent (Hain et al., 2016). The partially deprotected telomeres are 
recognised by p53 when the cell exits mitosis and enters G1 and such cells generally 
undergo apoptotic cell death. There are therefore numerous potential ways in which p53 
may respond to PLK1 inhibition. 
 
This chapter makes use of the HCT116 p53+/+ and p53-/- isogenic lines once again. 
However, in order to ensure that any observed effects are due to p53, an alternative 
approach of looking specifically at p53 function was utilised. By using siRNA, targeting 
p53, p53 could be silenced to allow investigation of p53-dependent effects in different 
established cell lines. Some experiments have also been carried out using MCF-7 cells, 
in which both the parental MCF-7 p53 wild type cells and MCF-7 cells that have had 
p53 knocked out by CRISPR technology have been tested. These cells were a kind gift 
from Professor Laki Buluwela. With the range of cell lines available, flow cytometry 
was used to allow analysis of cell cycle distribution and western blotting for 
determination of differences at the protein level of proteins of interest. 
 
4.2. Aims 
 
The aims of this chapter are to determine how p53 may offer a protective effect to 
cancer cells treated with PLK1 inhibitors. To do this the p53-dependent cell cycle 
distribution differences upon treatment with PLK1 inhibitors was investigated and the 
effects of PLK1 inhibitors on p53 and why they may have such effects was researched.  
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4.3. Results 
 
4.3.1. Treatment with PLK1 inhibitors results in a p53 dependent G1 peak 
	  
To try and address the reasons for p53 dependent differences in sensitivity to PLK1 
inhibitors, the aim was to determine if there were any obvious differences between the 
HCT116 p53+/+ and p53-/- cells upon treatment with PLK1 inhibitors. To initially 
address this, flow cytometry was used to assess the cell cycle distribution. Prior to 
harvesting, BrdU was added to the samples to allow representation of cells in S phase. 
BrdU is a thymidine analogue that is incorporated into the DNA during DNA synthesis. 
Once fixed, cells were incubated with an anti-BrdU antibody, FITC secondary antibody 
and finally labelled with propidium iodide to discriminate between differences in DNA 
content. Propidium iodide intercalates into the DNA and allows the stage of the cell 
cycle to be assessed, due to cells in G2/M containing double the DNA content compared 
to G1, and therefore double the propidium iodide.  
 
The HCT116 p53+/+ and p53-/- cells were seeded in 6 cm plates, and treated the 
following day with DMSO (vehicle control), 20 nM GSK461364 or 10 nM BI6727. 
After staining, cells were analysed on the flow cytometer and the resulting profiles are 
shown in Figure 4.1. As can be seen in Figure 4.1 the DMSO treated samples had 
similar cell cycle distributions between the p53+/+ and p53-/- cells. Upon treatment 
with either PLK1 inhibitor, the major effect is the presence of a sharp peak at 100K, 
representing a G2/M arrest, in both the p53+/+ and p53-/- lines. In both lines, a peak of 
<2N is present, representing cell death, and also >4N representing 
endoreduplication/multi or micro nucleation. Whilst these are fairly similar between the 
two lines, the one notable difference observed was the presence of a 2N peak, 
representing cells in G1, in the p53+/+ line that was absent from the p53-/- line.  
 
	   85	  
Whilst the two HCT116 lines are isogenic, during culture of cancer cells, changes can 
occur. To confirm whether the PLK1 inhibitor induced G1 cells are dependent on wild 
type p53, or if this could be a cell line specific outcome, p53 was silenced by siRNA in 
the wild type HCT116 line. siRNAs target specific mRNAs for degradation resulting in 
gene silencing. A non-silencing siRNA or siRNA targeting p53 were used to mimic the 
HCT116 p53+/+ and p53-/- lines respectively. After 24 hours of silencing the cells were 
harvested and western blotting was used to determine the protein levels. As can be seen 
in Figure 4.2 the p53 siRNA is effective, as the p53 levels are lower than the non-
silencing control. This showed that 24 hours of knockdown was a suitable time to carry 
out further treatments. HCT116 cells were then transfected with non-silencing siRNA or 
sip53 for 24 hours before treatment with PLK1 inhibitors for a further 24 hours. Flow 
cytometry was then used to determine the cell cycle distribution. The knockdown of p53 
had little effect on the cell cycle distribution of cells treated with the DMSO control. In 
the presence of PLK1 inhibitors, a G2/M arrest was observed in both the non-silencing 
and p53 silenced samples. However, as with the HCT116 p53+/+ and p53-/- lines the 
G1 peak was present in the p53 wild type (non-silencing) and whilst not absent, was 
much smaller in the p53 knockdown samples. Although in the HCT116 p53-/- cells the 
G1 peak was abolished and in the p53 siRNA treated samples it was only reduced, this 
could be explained by the fact that siRNA only results in knockdown and not knockout, 
therefore the residual p53 may be enough to cause an effect. 
 
To determine if this effect was an artefact of the HCT116 lines, U2OS (a p53 wild type 
osteosarcoma line) and MCF-7 (a p53 wild type breast cancer line) were also used in the 
same experiment. In order to allow a similar comparison to the HCT116 p53+/+ and 
p53-/- cells siRNA targeting p53 was again used. Figure 4.3 shows successful 
knockdown of p53 in U2OS cells after 24 hours. Actin has been probed to show even 
loading of protein samples in each well. U2OS cells were therefore treated with non-  
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Figure 4.1. Cells expressing wild type p53 show a partial G1 arrest in response to treatment with 
PLK1 inhibitors, GSK461364 or BI6727. HCT116 p53+/+ and p53-/- cells were treated for 24 hours 
with 20 nM GSK461364, 10 nM BI6727 or with DMSO as control. The cells were subsequently 
harvested and analysed by flow cytometry, with the resulting histograms shown (A) and quantification of 
this data for GSK461364 (B) and BI6727 (C). The data are representative of two independent 
experiments each conducted in triplicate. 
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Figure 4.2. Partial G1 arrest of HCT116 cells in response to treatment with the PLK1 inhibitors, 
GSK461364 or BI6727, is dependent upon p53. HCT116 cells were transfected with non-silencing 
siRNA or siRNA targeting p53 for 24 hours, before addition of 20 nM GSK461364, 10 nM BI6727 or 
DMSO for a further 24 hours. Cells were harvested for western blotting (A) or flow cytometry, with the 
resulting histograms shown in (B) and quantification of this data in (C). The data are representative of 
two independent experiments each conducted in duplicate. 
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silencing or p53 siRNA for 24 hours, before addition of GSK461364 (20 nM) or BI6727 
(10 nM) for a further 24 hours. Cells were then harvested and flow cytometry was again 
used to assess the cell cycle distribution. As can be seen in figure 4.3 the sip53 caused a 
slight change in the cell cycle profile compared to the non-silencing siRNA with DMSO 
treatment. Silencing p53 in these cells resulted in an increase in cell death. However, 
even with the differences observed under control conditions, when treated with PLK1 
inhibitors the trend of the cell cycle distribution was very similar to that observed in the 
HCT116 p53+/+ and p53-/- cells. With the GSK461364 drug the sip53 sample had a 
complete removal of the G1 peak compared to the non-silencing control, and the 
BI6727 drug showed a reduction of the G1 peak with silencing of p53.  
 
MCF-7 cells were then treated in the same way as U2OS cells. The knockdown after 24 
hours was effective, with loss of the p53 band as shown in the western blot in Figure 
4.4. Flow cytometry was then used. Figure 4.4 shows that the DMSO controls for MCF-
7 cells were similar with either the non-silencing or p53 siRNA. Upon treatment with 
PLK1 inhibitors the profiles were similar to that of HCT116 cells, with the predominant 
effect being the accumulation of cells in G2/M. Like the HCT116 p53+/+ cells, the non-
silencing control had a G1 peak. The p53 siRNA samples also had a G1 peak present, 
but this peak was smaller than that of the non-silencing control. 
 
These results show that cells expressing wild type p53 (HCT116 p53+/+ or non-
silencing HCT116, U2OS or MCF-7 cells) give rise to a higher proportion of cells in G1 
upon treatment with PLK1 inhibitors than in the absence of p53 (HCT116 p53-/- or 
sip53 in HCT116, U2OS or MCF-7 cells). Since p53 was shown to offer a protective 
effect upon inhibition of PLK1, and the presence of the G1 peak is the only noticeable 
difference between absence and presence of p53, this seems the most plausible 
explanation for the source of protection of p53 competent cancer cells. 
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Figure 4.3. Partial G1 arrest of U2OS cells in response to treatment with the PLK1 inhibitors, 
GSK461364 or BI6727, is dependent upon p53. U2OS cells were transfected with non-silencing siRNA 
or siRNA targeting p53 for 24 hours, before addition of 20 nM GSK461364, 10 nM BI6727 or DMSO for 
a further 24 hours. Cells were harvested for western blotting (A) or flow cytometry, with the resulting 
histograms shown in (B) and quantification of this data in (C). The data are representative of two 
independent experiments each conducted in duplicate. 
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Figure 4.4. Partial G1 arrest of MCF-7 cells in response to treatment with the PLK1 inhibitors, 
GSK461364 or BI6727, is dependent upon p53. MCF-7 cells were transfected with non-silencing 
siRNA or siRNA targeting p53 for 24 hours, before addition of 20 nM GSK461364, 10 nM BI6727 or 
DMSO for a further 24 hours. Cells were harvested for western blotting (A) or flow cytometry, with the 
resulting histograms shown in (B) and quantification of this data in (C). The data are representative of 
two independent experiments each conducted in duplicate. 
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4.3.2. PLK1 inhibitors lead to induction of p53 
 
The next aim was to determine what was occurring at the protein level in order to better 
understand the involvement of p53. HCT116 p53+/+ and p53-/- cells were again seeded 
in 6 cm plates, and were untreated or treated with DMSO, 20 nM GSK461364 or 10 nM 
BI6727. As the flow cytometry experiments were carried out after 24 hours of 
treatment, this time point was again selected. However, to gain insight into longer-term 
effects, 48 and 72 hours of treatment were also tested for this experiment. The cells 
were therefore harvested after 24, 48 or 72 hours of treatment and western blotting was 
used to determine protein levels.  As can be seen in Figure 4.5 the PLK1 levels increase 
at 24 hours of treatment compared to the untreated and DMSO treated controls. As 
PLK1 inhibitors only inhibit the activity of PLK1 and do not repress the expression of 
PLK1, this is expected as the cells arrest in mitosis where PLK1 is expressed at its 
highest levels (Golsteyn et al., 1994). At 48 and 72 hours the PLK1 levels are again 
reduced, presumably due to the transient nature of the mitotic arrest, resulting in cells 
eventually continuing through to exit or abort mitosis. Next, looking at the p53 levels 
showed that p53 was increasing upon treatment with PLK1 inhibitors. Correspondingly, 
p21, a classic p53 downstream target was also seen to increase. Phosphorylated gamma 
H2AX (S139) (γ-H2AX), a marker of DNA damage (specifically double strand breaks) 
was seen to increase, along with cleaved PARP, a marker of apoptosis. Interestingly, in 
the HCT116 p53+/+ line the level of γ-H2AX is lower upon treatment with PLK1 
inhibitors in comparison to the HCT116 p53-/- cells. Finally, phosphorylated histone H3 
at serine 10, a marker of mitosis, mirrored the PLK1 levels, suggesting cells accumulate 
at mitosis by 24 hours, and the cells subsequently exit mitosis at 48-72 hours. As a 
loading control, actin has also been probed, to show even loading of protein samples in 
each well. 
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Figure 4.5. Treatment of HCT116 cells with PLK1 inhibitors induces a p53 response. HCT116 
p53+/+ and p53-/- cells were either untreated, treated with DMSO or treated for 24, 48 or 72 hours with 
20 nM GSK461364 (A) or 10 nM BI6727 (B). Western blotting was then used with the antibodies 
indicated in the figure. 
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Figure 4.6. Treatment with PLK1 inhibitors induces p53. U2OS (A) and MCF-7 (B) cells were 
untreated, treated with 20 nM GSK461364 or 10 nM BI6727 for 24, 48 or 72 hours or DMSO as a vehicle 
control. Western blotting was then carried out with the antibodies indicated in the figure. 
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Again, to check if these results were specific to the HCT116 lines, MCF-7 and U2OS 
lines were also tested. In the first instance, MCF-7 and U2OS cells were untreated or 
treated with DMSO, 20 nM GSK461634 or 10 nM BI6727 for 24, 48 and 72 hours. 
Western blotting was again used to detect protein levels. Figure 4.6 shows the changes 
in the protein levels in MCF-7 and U2OS cells treated with both drugs. A similar result 
to HCT116 cells is observed with both these cell lines, with increasing levels of p53, 
p21, γ-H2AX and PARP cleavage upon treatment with both of the PLK1 inhibitors. The 
next experiment aimed to look at the role of p53 in this outcome, so HCT116 and U2OS 
cells were treated with either non-silencing siRNA or siRNA targeting p53. Figure 4.7 
shows the HCT116 cells. The p53 silencing was effective as can be seen from the much 
lower levels of p53, however, in both the non-silencing and the p53 knockdown samples 
the PLK1 levels peak at 24 hours of treatment and reduce at 48 and 72 hours. This 
suggested that p53 is not affecting the levels of PLK1 upon treatment with PLK1 
inhibitors. The same approach was used in the U2OS cells, and again the p53 
knockdown was successful as can be seen in Figure 4.8. A similar effect was observed 
in the U2OS cells in regards to the PLK1 levels, with the changes in levels throughout 
the treatment time being independent of p53. To further investigate the role of p53, 
parental MCF7 cells, and a derivative line in which p53 has been deleted using CRISPR 
(a kind gift from Professor Laki Buluwela), were treated with the PLK1 inhibitors. 
Figure 4.9 shows the changes in protein levels were very similar to that of the HCT116 
p53+/+ and p53-/- cells. In the parental line, p53 and p21 levels increase with increasing 
duration of PLK1 inhibition. In the p53 knock out MCF-7 line, as with the HCT116 
p53-/- line, the γ-H2AX levels were higher upon treatment with PLK1 inhibitors 
compared to the p53 wild type counterpart. The effects of PLK1 inhibitors therefore 
seem consistent between different cell lines.  
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A shorter time course was also used, with treatment times of 0, 1, 2, 4, 6, 12 and 24 
hours, in the HCT116 p53+/+ and p53-/- lines to determine what was occurring prior to 
24 hours of treatment (Figure 4.10). The DNA damage seen by γ-H2AX began to 
increase around 6 to 12 hours of treatment and peaked at 24 hours. The p53 levels 
showed a similar pattern of induction to that of the γ-H2AX levels.  
 
  
	   96	  
	  
Figure 4.7. HCT116 cells treated with PLK1 inhibitors in p53 silenced conditions. HCT116 cells 
were transfected with non-silencing siRNA or siRNA targeting p53. After 24 hours incubation, cells were 
subsequently treated with 20 nM GSK461364 (A) or 10 nM BI6727 (B) for 24, 48 or 72 hours. As a 
control cells were left untreated or treated with DMSO (vehicle control).  Cell lysates were then subjected 
to western blotting using the antibodies indicated in the figure. 
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Figure 4.8. The effect of PLK1 inhibitors on U2OS cells with silenced p53. U2OS cells were 
transfected with non-silencing siRNA or siRNA targeting p53. After 24 hours incubation, cells were 
subsequently treated with 20 nM GSK461364 (A) or 10 nM BI6727 (B) for 24, 48 or 72 hours. As a 
control cells were left untreated or treated with DMSO (vehicle control).  Cell lysates were then subjected 
to western blotting using the antibodies indicated in the figure. 
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Figure 4.9. The effects of PLK1 inhibitors on wild type and p53 knockout MCF-7 cells. Parental 
MCF-7 cells and MCF-7 cells that have had p53 knocked out by use of CRISPR technology were 
untreated, treated with DMSO or treated with 20 nM GSK461364 (A) or 10 nM BI6727 (B) for 24, 48 or 
72 hours. Cells were subsequently harvested and western blotting was used to assess protein levels using 
the antibodies indicated in the figure. 
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Figure 4.10. Inhibition of PLK1 in HCT116 cells results in induction of p53. HCT116 p53+/+ and 
p53-/- cells were treated with DMSO or treated for 0, 1, 2, 4, 6, 12 or 24 hours with 20 nM GSK461364 
(A) or 10 nM BI6727 (B). Western blotting was then used with the antibodies indicated in the figure. 
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4.3.3. The DNA Damage response leads to activation of p53 
 
PLK1 inhibitors are targeted protein kinase inhibitors and not standard genotoxic 
chemotherapeutic agents. Therefore the reason for observing a p53 response upon 
treatment with PLK1 inhibitors was uncertain. Numerous mechanisms can result in p53 
activation. However, due to the observation that γ-H2AX increases upon treatment with 
PLK1 inhibitors, activation of p53 by the DNA damage response pathway seemed the 
most possible mode of p53 induction. Upon DNA damage occurring, the protein kinases 
ATM and ATR phosphorylate p53 at serine 15 to activate p53. Therefore, to investigate 
if the DNA damage response was responsible for activating p53 upon treatment with 
PLK1 inhibitors, inhibitors of ATM and ATR (KU-55933 and VE-821 respectively) 
were used. As a positive control, etoposide, a topoisomerase inhibitor that results in 
DNA damage and activation of p53 was used. As can be seen in Figure 4.11 treatment 
with GSK461364 or etoposide resulted in increased levels of p53 and phosphorylated 
p53 (serine 15) compared to the DMSO control. However, one hour pretreatment with 
KU-55933 and VE-821, followed by 24 hours of treatment with GSK461364 or 
etoposide reduced the total p53 levels and the levels of serine 15 phosphorylation. This 
strongly suggested that p53 was being activated by the DNA damage response pathways 
upon inhibition of PLK1.  
 
To then determine if the DNA damage response was required for the G1 subset of cells 
observed by flow cytometry in wild type p53 cell lines, the ATM and ATR inhibitors 
were used, again with one hour of pretreatment, followed by 24 hours of treatment with 
GSK461364 or BI6727. Flow cytometry was then used to analyse the cell cycle 
distribution. Figure 4.12 shows that inhibition of the DNA damage response reduces the 
G1 peak, to a similar level as seen in the p53-/- line. (Additionally, the >4N peak was 
reduced with inhibition of ATM and ATR, although more cell death was seen 
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suggesting that due to lack of repair the cells die rather than arrest). Overall these 
findings suggest that activation of p53 through the DNA damage response is required 
for the accumulation of cells in G1 upon treatment with PLK1 inhibitors. 
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Figure 4.11. The DNA damage response pathway leads to induction of p53. HCT116 cells were 
pretreated for one hour with 10 µM ATM inhibitor, KU-55933, and/or ATR inhibitor, VE-821. Cells were 
subsequently treated for a further 24 hours with 20 nM GSK461364 or 50 µM etoposide before 
harvesting. Western blotting was used with the antibodies indicated in the figure. 
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Figure 4.12. The DNA damage response pathway is required for p53 dependent cell cycle effects. 
HCT116 p53+/+ and p53-/- cells were treated with DMSO or 10 µM KU-55933 and VE-821 for one 
hour, before addition of DMSO, 20 nM GSK461364 or 10 nM BI6727 for a further 24 hours. Cells were 
subsequently harvested and stained for flow cytometry analysis. The resulting histograms are shown in 
(A) and quantification of the percentage of cells in each phase of the cell cycle is shown for HCT116 
p53+/+ in (B) and HCT116 p53-/- in (C). 
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4.3.4. Phosphorylation of p53 at serine 15 is involved in the presence of the p53 
dependent G1 subset of cells 
 
Serine 15 has been shown to be the activating phosphorylation site of p53 upon DNA 
damage and is phosphorylated by ATM and ATR (Loughery et al., 2014). Substitution 
of serine to alanine is a useful tool for blocking phosphorylation. Using the IPTG 
inducible Lacswitch II system, H1299 (a p53 null lung cancer cell line) were stably 
transfected to express either wild type p53 or p53 with a serine 15 to alanine 
substitution upon addition of IPTG. These cells could then be used to determine if 
serine 15 was essential for the previous p53 dependent results that had been observed. 
This would allow confirmation of the role of the DNA damage signalling pathways in 
activating p53 following inhibition of PLK1. Figure 4.13 shows that in the absence of 
IPTG p53 is not detected at a high level in either the wild type or S15A cells. However 
upon addition of IPTG there is a dose dependent increase in p53 levels. HCT116 cells 
have been included as a control for comparison of endogenous levels of p53, to ensure 
the system is not giving rise to overexpressed levels of p53. Loss of serine 15 
phosphorylation impairs the ability of p53 to induce downstream target genes such as 
p21, as seen in Figure 4.13. Next, flow cytometry, using the same experimental set up 
as previously shown, was used. As can be seen in Figure 4.14 under DMSO conditions 
both the H1299 S15 and S15A cell lines had similar profiles upon addition of IPTG. As 
a control the H1299 p53 null parental cell line was also tested. Figure 4.14 shows that 
the parental H1299 cells have an increase in the proportion of cells in S phase and 
decrease in the proportion of cells in G1 under DMSO conditions, compared to the 
inducible H1299 lines. Upon treatment with PLK1 inhibitors a similar result was again 
observed, with the wild type p53 (S15WT) cells showing an increased proportion of 
cells in G1 in comparison to the S15A cells or H1299 parental cells. This suggests that 
S15 is playing a role in the outcome of inhibition of PLK1.  
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Figure 4.13. Induction of p53 in H1299 p53 inducible lines. IPTG inducible H1299 cells expressing 
wild type p53 or p53 with serine 15 substituted to alanine were treated with 0, 10, 25, 50, 75 or 100 µM 
IPTG for 16 hours. Cells were harvested and western blotting was used to analyse the levels of p53, p21 
and actin protein levels. HCT116 cells (wild type p53) were used as a reference for endogenous p53 
levels. 
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Figure 4.14. p53 serine 15 is involved in the accumulation of cells in G1. Parental H1299 cells or 
inducible H1299 cells expressing wild type p53 or p53 S15A were treated with 100 µM IPTG for 16 
hours. Cells were then treated with DMSO, 20 nM GSK461364 or 10 nM BI6727 for a further 24 hours, 
with 100 µM IPTG being maintained throughout. Cells were harvested and flow cytometry was used to 
assess the cell cycle distribution. Resulting histograms (A) and quantification of cells in each phase of the 
cell cycle (B) are shown.  
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4.3.5. PLK1 Inhibition leads to DNA Damage 
 
As shown, the two inhibitors of PLK1 led to DNA damage as observed by induction of 
γ-H2AX. However, small molecule kinase inhibitors are notoriously promiscuous, and 
often have a lack of specificity and therefore off target effects can occur. To inhibit 
PLK1 by a different method, to see if the DNA damage was occurring as a specific 
result of inhibiting PLK1 or an off target effect of the inhibitors, siRNA targeting PLK1 
was utilised. A mock treatment, using the transfection reagents with no siRNA, non-
silencing siRNA and siPLK1 were used. In addition, as a comparison, treatments with 
GSK461634 and BI6727 were also used. Figure 4.15 shows that silencing PLK1 with 
siRNA results in γ-H2AX induction. When compared to treatment with either PLK1 
inhibitor, it can be seen that the levels of γ-H2AX are fairly similar, as are the levels of 
cleaved PARP. This suggested that the DNA damage occurring was a direct result of 
inhibiting PLK1 and not an off target effect. Although, the induction of p53 is much less 
with silencing of PLK1 compared to treatment with PLK1 inhibitors. As an additional 
control, the samples that were transfected with PLK1 siRNA, were treated with the 
PLK1 inhibitors in combination. This would allow determination of any additive 
effects, which would again suggest off target effects were occurring. If the DNA 
damage resulting from knocking down PLK1 was a result of a different source from the 
DNA damage caused by the inhibitors, then double the amount of DNA damage would 
have been expected. However, as the figure shows, the γ-H2AX levels with 
combination of PLK1 siRNA and PLK1 inhibitor are consistent with knocking down 
PLK1 or treating with PLK1 inhibitor alone. This strongly implies the PLK1 inhibitors 
are specific, and inhibiting PLK1 results in DNA damage. 
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Figure 4.15. Inhibition of PLK1 leads to DNA damage. HCT116 p53+/+ and p53-/- cells were 
transfected with a mock transfection (transfection reagent alone), non-silencing siRNA or siRNA 
targeting PLK1. After 24 hours cells were treated with DMSO, 20 nM GSK461364 or 10 nM BI6727 for 
a further 24 hours. Cells were then harvested and western blotting was used with the antibodies indicated 
in the figure. 
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4.3.6. The DNA damage is not caspase dependent 
 
Some reports show that DNA damage occurring as a result of prolonged mitosis is 
caspase dependent and p53 recognises and responds to this damage in the subsequent 
G1 after mitotic exit (Hain et al., 2016). Z-VAD-FMK, a pan caspase inhibitor, blocks 
the initial stages of activation of apoptosis. This prevents cells undergoing apoptosis as 
a method of cell death. To address if the DNA damage observed is caspase dependent 
and a result of initiation of apoptosis, cells were pre-treated for one hour with Z-VAD-
FMK. GSK461364 or BI6727 were then added to the cells for a further 24 or 48 hours. 
As can be seen in Figure 4.16 Z-VAD-FMK successfully blocks apoptosis as seen from 
the reduction of cleaved PARP. Whilst apoptosis is inhibited, the DNA damage 
observed is very similar in level in the presence or absence of Z-VAD-FMK. This 
shows that the DNA damage occurring with treatment of PLK1 inhibitors is not likely 
to be caspase dependent and a consequence of apoptosis. 
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Figure 4.16. The DNA damage is not caspase dependent. HCT116 p53+/+ and p53-/- cells were 
pretreated for one hour with 25 µM Z-VAD-FMK or DMSO (vehicle control) before addition of (A) 20 
nM GSK461364 or (B) 10 nM BI6727 for 24 or 48 hours. Cells were then harvested at the indicated time 
points and western blotting was used to assess protein levels using the antibodies shown in the figure. 
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4.4.  Discussion 
	  
This chapter has shown that when PLK1 inhibitors are applied, p53 is induced. Further 
experiments have shown that this induction of p53 occurs through the DNA damage 
response pathways, as inhibition of ATM and ATR (two DNA damage response protein 
kinases) alleviates the activation of p53. The DNA damage resulting from PLK1 
inhibition shown here is in agreement with previous studies that have also observed 
DNA damage occurring as a result of PLK1 inhibition (Driscoll et al., 2014). 
Additionally, the DNA damage was shown to be specific to inhibition of PLK1 and not 
an off target effect of the ATP competitive small molecule inhibitors tested, as use of 
siRNA targeting PLK1 also resulted in DNA damage. This DNA damage could 
therefore be the activating stimulus for p53, and may be required for the p53 mediated 
protective effect. A DNA damage response has previously been shown to occur upon 
prolonged mitotic delay. However, this was suggested to be caspase dependent (Hain et 
al., 2016). Use of a pan-caspase inhibitor showed that the DNA damage occurring in 
response to PLK1 inhibitors did not appear to be caspase dependent, therefore 
suggesting that this was not the cause of DNA damage in this case. Further 
investigations should therefore be carried out to determine the cause of the DNA 
damage observed upon inhibition of PLK1. 
 
The p53-dependent differences observed in cell cycle distribution upon treatment with 
PLK1 inhibitors highlight a plausible source of protection through the identification of a 
p53-dependent G1 subset of cells. It has been shown that cells which do not 
successfully complete mitosis and go on to re-enter the cell cycle with an abnormal 
chromosome complement will be arrested by p53, and most likely undergo apoptosis 
(Hayashi and Karlseder, 2013). This therefore rules out cells with a complement of 
DNA greater than 2N as being cells likely to recover and survive PLK1 inhibition in a 
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p53-dependent manner. This leaves cells arrested in G2 or mitosis and cells 
accumulating in G1 as the only plausible surviving cells. However, cells are also 
arrested in G2/mitosis in the absence of p53, which further implicates the G1 cells as 
being a more probable source of p53 dependent protection. It should be noted that 
functional isoforms of p53 exist, and some of these isoforms are present in the HCT116 
lines. The HCT116 p53-/- line, whilst lacking full-length p53 expression, does express 
shorter p53 isoforms (Murray-Zmijewski, Lane and Bourdon, 2006). The effects 
observed could potentially be due to the activity of the isoforms. However, the siRNA 
used to silence p53 targets exon 7 of p53. By targeting this exon all p53 isoforms are 
silenced, therefore suggesting that the effects observed are due to full-length p53. The 
G1 subset of cells are reliant on activation of p53, as inhibiting ATM and ATR or 
substituting the critical residue on p53, serine 15, to alanine results in a cell cycle 
distribution similar to that of cells lacking p53. Although activation of p53 is required 
by ATM and ATR to exert p53 dependent effects in regards to PLK1 inhibition, it is not 
known whether the DNA damage induced by PLK1 inhibition is a critical stimulus for 
this response or whether basal levels of p53 activity or some other stimulus are 
sufficient to exert such an effect. Further work could attempt to address this question, 
and could also determine if serine 15 is the only critical residue, or if other sites of post-
translational modifications are equally as important. 
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Chapter 5 : p53 plays a novel role in centrosome 
separation during early mitosis  
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5.1. Background 
	  
One of the results of inhibition of PLK1 is a p53 response, ultimately leading to 
decreased sensitivity to PLK1 inhibitors. However, the mechanism by which p53 elicits 
this protective effect is unclear. The data shown above, suggests that a subset of p53 
competent cells can accumulate in G1 upon treatment with PLK1 inhibitors. However, 
the mechanism behind this is unknown. PLK1 has been shown to have roles in DNA 
replication in S phase (H. Yim and Erikson, 2009; Song et al., 2011; Shen et al., 2013), 
there is therefore potential for a p53 dependent effect in the early parts of the cell cycle. 
This could be the reason for G1 cells to accumulate in a p53-dependent fashion. 
Alternatively, these cells may be able to complete mitosis even in the presence of PLK1 
inhibitors. It has been widely accepted that during mitosis, transcription is repressed due 
to the highly condensed chromatin, making promoters inaccessible, and the 
displacement of specific RNA polymerase II factors from the chromosomes (Gottesfeld 
and Forbes, 1997). This would suggest that as a transcription factor, p53 would not be 
able to exhibit any effects during mitosis. Although one study suggested that some 
transcriptional activity can remain during mitosis, as Cyclin B1 was shown to be 
transcribed during mitosis in Hela cells (Sciortino et al., 2001). There are therefore 
several possible ways in which p53 may allow the accumulation of cells in G1 upon 
treatment with PLK1 inhibitors. As this is the most plausible means by which p53 
provides a protective effect to some cancer cells upon application of PLK1 inhibitors, 
the mechanism by which this occurs is of great interest. 
 
Time-lapse microscopy has become a highly useful tool for investigating mitosis and 
other aspects of cell movements. Generation of movies allows analysis of individual 
cells, and can allow determination of timings of the cell cycle, with particular focus on 
mitotic duration. As PLK1 inhibitors result in a mitotic arrest, it is therefore beneficial 
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to be able to interrogate mitosis in such a way. Time-lapse microscopy has been 
effectively utilised throughout this chapter, along with immunofluorescence, which still 
provides an excellent method of determining the localisation of specific proteins within 
a cell.  
 
5.2. Aims 
	  
The aim of this chapter is to attempt to determine the mechanism(s) that results in the 
p53-dependent accumulation of a subset of cells in G1 upon treatment with PLK1 
inhibitors, as this could potentially underpin the protective effect that p53 offers some 
cancer cells as observed previously. 
 
5.3. Results  
 
5.3.1. Cells accumulating in G1 in a p53 dependent manner complete mitosis 
 
While there are few reports on the role of PLK1 outwith mitosis, some publications 
implicate PLK1 as having a role in S phase (Song et al., 2011; Song, Liu and Liu, 2012; 
Mandal and Strebhardt, 2013). Therefore, we wondered if the DNA damage was 
actually occurring earlier in the cell cycle upon treatment with PLK1 inhibitors and this 
resulted in the p53 dependent G1 cells observed. Cells were synchronised in order to 
investigate whether the DNA damage occurs earlier in the cell cycle, and thus results in 
cells arresting at G1/S prior to completing mitosis. Serum starvation was used as a 
method of synchronising the cells at entry to G1. The first step was to estimate how 
long it takes the cells to reach different phases of the cell cycle. Flow cytometry was 
used to assess this, with cells being serum starved for 24 hours, before re-addition of 
serum to allow entry into G1, and harvesting at different time points. Figure 5.1 shows 
that cells reach the G1/S boundary by around 6 hours, are mainly in S phase at 12 hours, 
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M phase at 16 hours and the full cycle is completed by 24 hours. However, the 
population begins to become asynchronous very quickly.  
 
Using these times as a basis, cells were serum starved for 24 hours before re-addition of 
serum in the presence of DMSO or 20 nM GSK461634 for 0, 3, 12, 16 and 24 hours. 
Figure 5.2 shows that in the presence of DMSO, the HCT116 p53+/+ and p53-/- cells 
have very similar profiles at each of the time points tested. In the presence of 
GSK461364 the profiles are also very similar at 0, 3, 12 and 16 hours, however at 24 
hours differences begin to emerge. The G1 peak in both the p53+/+ and p53-/- cells is 
almost absent at 16 hours, but at 24 hours it increases in size only in the p53+/+ cells. 
The G1 peak must therefore arise from cells that have successfully undergone 
cytokinesis in the presence of the PLK1 inhibitor, and not as a result of arresting prior to 
entry into S phase.  
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Figure 5.1. Synchronisation of HCT116 cells. HCT116 cells were serum starved for 24 hours. Serum 
was then reintroduced to the cells before harvesting at 0, 1, 6, 12, 16 or 24 hours after the addition of 
serum. Flow cytometry was then used to assess the cell cycle profiles. Resulting histograms are shown in 
(A) and the quantification of this data is represented in (B). 
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Figure 5.2. The G1 subset of cells arise from cells undergoing mitosis in the presence of 
GSK461364. HCT116 p53+/+ and p53-/- cells were serum starved for 24 hours. Serum was then added 
back to cells for one hour before the addition of DMSO or 20 nM GSK461364. Cells were subsequently 
harvested at 0, 3, 12, 16 or 24 hours. Flow cytometry was used to assess the cell cycle profiles. Resulting 
histograms are shown in (A) and the quantification of this data is represented for DMSO in (B) and 
GSK461364 in (C). 
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5.3.2. p53 reduces the duration of mitotic arrest upon inhibition of PLK1 
 
As it was shown that the p53-dependent subset of cells appearing in G1 after treatment 
with PLK1 inhibitors were arising from completing mitosis in the presence of the drug, 
the next aim was to determine if the mitotic arrest was different in the absence or 
presence of p53. To do this, HCT116 p53+/+ and p53-/- cells were used. Cells were 
seeded in a 24-well plate format, and treated with different doses of GSK461364 or 
BI6727, or treated with DMSO as a vehicle control. Following treatment, the plate was 
mounted on the Zeiss Axiovert microscope. Positions were then set within each well to 
allow the progress of the cells to be followed in phase contrast. The cells were imaged 
every 4 minutes over 250 frames. This allowed the production of movies in which cells 
could be seen rounding up to indicate entry of mitosis through to the decision of cellular 
fate, either successful cytokinesis, apoptosis, mitotic slippage or mitotic arrest.  To 
determine if differences existed between the two HCT116 lines, the duration between 
entry to mitosis and exit from mitosis (successful cytokinesis, apoptosis or mitotic 
slippage) was measured. For each condition 50 cells entering mitosis were followed and 
the resulting times taken to reach mitotic exit were plotted on graphs. 
 
 Figure 5.3 shows that under DMSO conditions, HCT116 p53+/+ and p53-/- cells have a 
short mitotic duration, with 100% of cells exiting mitosis in the time frame analysed. 
The two cell lines show little difference in their mitotic duration under normal, 
unstressed conditions. Next, the effect of increasing doses of GSK46164 was assessed. 
5 nM, 10 nM and 20 nM concentrations of GSK461364 were tested. In the HCT116 
p53+/+ line 5 nM of drug results in a slight increase in mitotic duration. 10 nM causes a 
further delay in mitotic exit, with 20 nM causing the most adverse effect on mitotic 
duration. Not only was there a delay in mitotic exit with increasing concentrations of 
GSK461364, there was also a decreased number of cells ever exiting mitosis in the time 
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frame followed. GSK461364 clearly results in a mitotic arrest with increased severity in 
a dose dependent fashion. Next, the HCT116 p53-/- cells were analysed in the same 
format. Again GSK461364 resulted in a mitotic arrest with increasing severity in a dose 
dependent manner. Although under DMSO conditions there is little difference between 
the mitotic durations, upon treatment with PLK1 inhibitor the p53+/+ cells show a 
shorter delay in mitosis compared to the p53-/- cells. This could suggest that the PLK1 
inhibitor has less effect on wild type p53 cells, somehow allowing them to complete 
mitosis at a rate more similar to the normal homeostatic conditions. However, in the 
absence of p53 cells are delayed in mitosis for a much longer time, preventing cells 
returning to G1. This supports the observations of the flow cytometry data that show 
wild type p53 results in a G1 subset of cells that is not present in p53 deficient cells.  
 
BI6727 was also used in the same assay, with a similar trend of results to that of 
treatment with GSK461364, as shown in Figure 5.4. This shows that the effects 
observed are not specific to one PLK1 inhibitor, but occur with two independently 
developed PLK1 inhibitors. 
 
Although a very interesting observation, this could be a general consequence of 
inhibiting mitosis, rather than a specific effect of PLK1 inhibition. In order to check 
this, Taxol was used in the same experiment. Figure 5.5 shows that whilst increasing 
concentrations of Taxol results in an increased delay in mitotic exit, there is little 
difference in the duration of mitosis between the p53+/+ and p53-/- lines upon treatment 
with Taxol. This suggests that the effect observed is more specific to inhibition of PLK1 
and not a general effect of inhibiting mitosis. 
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Figure 5.3. p53 reduces the duration of mitotic arrest upon treatment with GSK461364. HCT116 
p53+/+ (A) and p53-/- cells (B) were treated with 5, 10 or 20 nM GSK461364 or DMSO as a vehicle 
control. Time-lapse analysis was then used to determine the duration of mitosis. Both graphs represent the 
cumulative data from 50 cells for one experiment and are representative of three replicates. 
	  
HCT116&p53&+/+&GSK461364&&
A
HCT116&p53&0/0&GSK461364&
B 
0&
10&
20&
30&
40&
50&
60&
70&
80&
90&
100&
0& 16
&
32
&
48
&
64
&
80
&
96
&
11
2&
12
8&
14
4&
16
0&
17
6&
19
2&
20
8&
22
4&
24
0&
25
6&
27
2&
28
8&
30
4&
32
0&
33
6&
35
2&
36
8&
38
4&
40
0&
Cu
m
ul
a:
ve
&p
er
ce
nt
ag
e&
ce
lls
&(%
)&
Time&from&mito:c&entry&(minutes)&
+/+&DMSO&
+/+&5&nM&
+/+&10&nM&
+/+&20&nM&
0&
10&
20&
30&
40&
50&
60&
70&
80&
90&
100&
0& 16
&
32
&
48
&
64
&
80
&
96
&
11
2&
12
8&
14
4&
16
0&
17
6&
19
2&
20
8&
22
4&
24
0&
25
6&
27
2&
28
8&
30
4&
32
0&
33
6&
35
2&
36
8&
38
4&
40
0&
Cu
m
ul
a:
ve
&p
er
ce
nt
ag
e&
ce
lls
&(%
)&
Time&from&mito:c&entry&(minutes)&
0/0&DMSO&
0/0&5&nM&
0/0&10&nM&
0/0&20&nM&
	   124	  
	  
	  
Figure 5.4. p53 reduces the duration of mitotic arrest upon treatment with BI6727. HCT116 p53+/+ 
(A) and p53-/- cells (B) were treated with 5, 10 or 20 nM BI6727 or DMSO as a vehicle control. Time-
lapse analysis was then used to determine the duration of mitosis. Both graphs represent the cumulative 
data from 50 cells for one experiment and are representative of three replicates. 
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Figure 5.5. p53 has no effect on the duration of mitotic arrest upon treatment with Taxol. HCT116 
p53+/+ (A) and p53-/- cells (B) were treated with 10 or 20 nM Taxol or DMSO as a vehicle control. 
Time-lapse analysis was then used to determine the duration of mitosis. Both graphs represent the 
cumulative data from 50 cells for one experiment and are representative of two replicates.  
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To then determine if this effect was specific to p53 or just a cell line dependent effect, 
wild type MCF-7 (WT) cells and MCF-7 cells in which p53 has been knocked out by 
CRISPR (p53 KO) were tested. The first experiment tested the effect of GSK461364 on 
the MCF-7 WT and MCF-7 p53 KO cells. Figure 5.6 shows that under DMSO 
conditions the duration of mitosis is very similar between the WT and p53 KO cells. In 
both cases 100% of cells exited mitosis in the given time. As with the HCT116 cells, 
there was a dose dependent increase in the duration of mitotic arrest upon treatment 
with GSK461364 in both the WT and p53 KO cells. However, again the p53 deficient 
cells showed a more severe mitotic arrest in comparison to the p53 wild type cells at the 
equivalent doses of GSK461364. 
 
As the MCF-7 cells showed a similar effect to the HCT116 cells upon inhibition of 
PLK1, the effects observed with treatment of Taxol were then tested. MCF-7 WT and 
p53 KO cells were treated with 20 or 40 nM Taxol or DMSO as a vehicle control. The 
resulting mitotic durations in Figure 5.7 showed that whilst increasing concentrations of 
Taxol resulted in an increase in the severity of the mitotic arrest, there was little 
difference between the MCF-7 WT and p53 KO cells. These findings support the results 
observed with the HCT116 cells, and suggest that the delay in mitotic exit upon 
treatment with PLK1 inhibitors is in fact dependent on the lack of p53 and not a cell line 
specific result. 
 
To further enhance these experiments a similar approach was used, but this time to 
allow the DNA to be focused upon, SiR-DNA was used. HCT116 p53+/+ and p53-/- 
cells were seeded in specialised 8-well chambers and stained with 100 nM SiR-DNA. 
After staining the cells were treated with DMSO or 20 nM GSK461364. Cells were 
subsequently imaged using a Deltavision Elite microscope for 250 time points at 4 
minutes intervals. 
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Figure 5.6. p53 reduces the duration of mitotic arrest upon treatment with GSK461364 in MCF-7 
cells. MCF-7 wild type (WT) (A) and p53 KO cells (B) were treated with 5, 10 or 20 nM GSK461364 or 
DMSO as a vehicle control. Time-lapse analysis was then used to determine the duration of mitosis. Both 
graphs represent the cumulative data from 50 cells for one experiment and are representative of two 
replicates. 
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Figure 5.7. p53 has no effect on the duration of mitotic arrest upon treatment with Taxol in MCF-7 
cells. MCF-7 WT (A) and p53 KO cells (B) were treated with 20 or 40 nM Taxol or DMSO as a vehicle 
control. Time-lapse analysis was then used to determine the duration of mitosis. Both graphs represent the 
cumulative data from 50 cells for one experiment and are representative of two replicates.  
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The resulting movies, of which an electronic copy can be found in the appendix, 
allowed analysis of the DNA in the fluorescent channel and the cell in the phase 
contrast reference image. Representative images are shown in Figure 5.8 A, where a still 
at approximately 16 hours of treatment is shown. Whilst both the p53+/+ and p53-/- 
cells under DMSO conditions show few cells with condensed chromosomes (i.e mitotic 
cells), only the p53-/- cells show a much greater number of cells with condensed 
chromosomes upon treatment with GSK461364. Quantitative analysis of these movies 
is represented in Figure 5.8 B. Here it can be seen that under DMSO conditions the 
median duration of mitosis was very similar in the presence and absence of p53. 
However, when GSK461364 was applied the median duration of p53+/+ cells was 100 
minutes, whilst the p53-/- cells had a median duration of 280 minutes. There was 
therefore a significant increase in the duration of mitosis in p53 deficient cells treated 
with GSK461364 compared to p53 competent cells. These findings support the data 
obtained by determining the duration of mitosis by use of phase contrast alone.	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Figure 5.8. Upon inhibition of PLK1, p53 reduces the duration of mitotic delay. HCT116 p53+/+ and 
p53-/- cells were stained with SiR-DNA, treated with DMSO or 20 nM GSK461364 and imaged by time-
lapse microscopy on a Deltavision Elite microscope. (A) Representative images of approximately 16 
hours of treatment. (B) Box plots (showing median and quartiles) presenting the duration of mitosis of 22 
HCT116 p53+/+ and 22 HCT116 p53-/- cells treated with DMSO and 77 HCT116 p53+/+ and 77 
HCT116 p53-/- cells treated with 20 nM GSK461364. P values were calculated using a Student’s t-test. 
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5.3.3. The presence of p53 results in an increased mitotic index upon inhibition of 
PLK1 
	  
To further investigate the mitotic arrest an alternative experimental procedure was used. 
Whilst normal cell cycle analysis does not discriminate G2 cells from mitotic cells, 
assays have been developed in order to quantify the mitotic index of a population of 
cells. Use of an antibody against phosphorylated histone H3 at serine 10, a site that is 
only phosphorylated during mitosis, allows calculation of the percentage of cells that 
are in mitosis at the time of harvesting. HCT116 p53+/+ and p53-/- cells were treated 
for 4 and 8 hours with 10 and 20 nM GSK461364. After fixation and incubation with 
first the phosphorylated histone H3 serine 10 antibody, and then the FITC secondary 
antibody, cells were stained with propidium iodide and analysed on the flow cytometer. 
The percentage of cells that were positive for phosphorylated histone H3 (serine 10), 
and therefore mitotic, were measured and plotted as a graph. The results represented in 
Figure 5.9 show that under DMSO conditions there is little difference between the 
mitotic index of the HCT116 p53+/+ and p53-/- cells. However, at both 10 and 20 nM 
GSK461364 and at both 4 (Figure 5.9 A) and 8 (Figure 5.9 B) hours of treatment the 
mitotic index is greater in the HCT116 p53-/- cells compared to the p53+/+ cells. This 
supports the findings from the experiments assessing the duration of mitotic arrest by 
time-lapse microscopy, where the p53-/- cells showed an increased duration of mitotic 
arrest compared to the p53+/+ cells. To check this was not specific to GSK461364, 10 
and 20 nM BI6727 was also tested for 8 hours of treatment. Figure 5.9 C shows that 
again, at both concentrations of BI6727 the p53-/- cells have an increased mitotic index 
in comparison to the p53+/+ cells.  
	  
	   132	  
	  
	  
Figure 5.9. HCT116 p53-/- cells show an increased mitotic index upon treatment with PLK1 
inhibitors in comparison to HCT116 p53+/+ cells. HCT116 p53+/+ and p53-/- cells were treated with 
10 nM or 20 nM GSK461364 (A+B) or BI6727 (C) for 4 hours (A) or 8 hours (B+C). Cells were 
subsequently harvested, fixed, stained with phosphorylated histone H3 (serine 10) antibody, followed by 
staining with a FITC secondary antibody, and finally labelled with propidium iodide. Flow cytometry was 
then used to calculate the percentage of cells that were positive for phospho-histone H3 (S10) and 
therefore mitotic. The graphs are representative of two independent experiments.  
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5.3.4. Inhibition of DNA damage-induced activation of p53 upon PLK1 inhibition 
increases the duration of mitotic arrest 
	  
The next aim was to determine how p53 results in a quicker decision in mitosis in the 
presence of PLK1 inhibitors. Previously, it had been shown that the protein kinases 
ATM and ATR were involved in the activation of p53 upon inhibition of PLK1. 
Therefore, to test if the activation of p53 by the DNA damage response is required for 
the observed differences in mitotic duration, the assay measuring the mitotic duration 
was repeated in the presence or absence of ATM and ATR inhibitors. Figure 5.10 shows 
that in comparison to the DMSO control, addition of ATM and ATR inhibitors (KU-
55933 and VE-821) alone resulted in a slight delay in mitosis. However, the vast 
majority of cells were exiting mitosis in the time frame analysed. Treatment with 
GSK461364 resulted in an increased mitotic duration as previously observed. 
Pretreatment with ATM and ATR inhibitors followed by treatment with GSK461364 in 
the HCT116 p53+/+ line resulted in an increase in the severity of the mitotic arrest in 
comparison to GSK461364 treatment alone. However, in the HCT116 p53-/- line 
GSK461364 treatment alone or in combination with ATM and ATR inhibitors showed 
virtually indistinguishable differences in mitotic duration. This suggested that the DNA 
damage response leading to activation of p53 is, at least in part, required to allow a 
quicker mitotic duration in the presence of PLK1 inhibitors. The same experiment was 
carried out with BI6727 in place of GSK461364. Figure 5.11 shows that a very similar 
result was obtained. 
 
These observations suggest that p53 does require activation via the DNA damage 
response pathways for this mitotic effect to occur. However, it doesn’t distinguish 
between the possibility that p53 is actively involved during this stage of mitosis or if the 
initial delay actually arises from events that occur prior to mitosis. 
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Figure 5.10. Mitotic effect of inhibiting the DNA damage response upon treatment with 
GSK461364. HCT116 p53+/+ (A) and p53-/- (B) cells were pretreated for 1 hour with DMSO or 10 µM 
ATM and ATR inhibitors, KU-55933 and VE-821 respectively. Cells were subsequently treated with 
DMSO or 10 nM GSK461364. Time-lapse analysis was then used to determine the duration of mitosis. 
Both graphs represent the cumulative data from 50 cells for one experiment and are representative of two 
replicates.  
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Figure 5.11. Mitotic effect of inhibiting the DNA damage response upon treatment with BI6727. 
HCT116 p53+/+ (A) and p53-/- (B) cells were pretreated for 1 hour with DMSO or 10 µM ATM and 
ATR inhibitors, KU-55933 and VE-821 respectively. Cells were subsequently treated with DMSO or 10 
nM BI6727. Time-lapse analysis was then used to determine the duration of mitosis. Both graphs 
represent the cumulative data from 50 cells for one experiment and are representative of two replicates. 
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5.3.5. p53 does not cause a delay in mitotic entry upon inhibition of PLK1 
 
In order to determine if cells traverse mitosis more successfully in the presence of p53 
due to a delay in mitotic entry, allowing cells to somehow prepare prior to entry to 
mitosis and resulting in a more successful chance of completing mitosis, flow cytometry 
was used. To give a measure of the number of cells entering mitosis it was necessary to 
block mitotic exit, thereby allowing the accumulation of cells to represent a measure of 
mitotic entry rate. Nocodazole, a mitotic inhibitor that interferes with the polymerisation 
of microtubules, was used in order to prevent cells exiting mitosis. Therefore, with use 
of Nocodazole and/or PLK1 inhibitor the effect of PLK1 inhibition on mitotic entry 
could be assessed. HCT116 p53+/+ and p53-/- cells were treated with DMSO, 10 nM 
GSK461364, 20 nM GSK461364, Nocodazole, Nocodazole and 10 nM GSK461364 or 
Nocodazole and 20 nM GSK461364 for 4 and 8 hours. Flow cytometry was then used 
to analyse the percentage of cells in mitosis by detecting cells that were positive for 
phospho-histone H3 (S10). Figure 5.12 shows that upon treatment with 10 nM or 20 nM 
GSK461364 the mitotic index is increased compared to the DMSO control. Treatment 
with Nocodazole alone resulted in a high percentage of mitotic cells, showing the cells 
were being prevented from exiting mitosis in both the p53+/+ and p53-/- lines. In 
combination with Nocodazole, GSK461364 had little effect on the proportion of cells in 
mitosis. This therefore suggested that cells were not being delayed in their entry to 
mitosis upon inhibition of PLK1, as in this case the percentage of mitotic cells would 
decrease in combination of Nocodazole and GSK461364 compared to Nocadozole 
alone. 
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Figure 5.12. There is not a p53 dependent delay in mitotic entry upon treatment with GSK461364. 
HCT116 p53+/+ (A+C) and p53-/- (B+D) cells were treated with 10 nM or 20 nM GSK461364, 3.3 µM 
Nocodazole or a combination of 10 nM or 20 nM GSK461364 with 3.3 µM Nocodazole for 4 hours 
(A+B) or 8 hours (C+D). Cells were subsequently harvested, fixed, stained with phosphorylated histone 
H3 (serine 10) antibody, followed by staining with a FITC secondary antibody, and finally labelled with 
propidium iodide. Flow cytometry was then used to calculate the percentage of cells that were positive for 
phospho-histone H3 (S10) and therefore mitotic. The graphs are representative of two independent 
experiments.   
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5.3.6. There is not a p53-dependent difference in PLK1 activity upon inhibition of 
PLK1 
 
As there was not a p53-dependent delay in mitotic entry observed when PLK1 inhibitors 
were applied, perhaps the activity of PLK1 was higher in HCT116 p53+/+ cells 
compared to p53-/- cells upon inhibition of PLK1. This could allow p53 competent cells 
to complete mitosis due to having sufficient levels of PLK1 to allow mitotic 
progression. To test this hypothesis a phosphorylation target of PLK1, threonine 680 in 
BubR1, was measured (Suijkerbuijk et al., 2012). As PLK1 is most active in mitosis, 
and upon inhibition of PLK1 there are many more cells in mitosis in the HCT116 p53-/- 
line compared to the p53+/+ line, the differences in the number of mitotic cells had to 
be considered. In order to circumvent this problem, cells were treated with Nocodazole, 
or Nocodazole in combination with PLK1 inhibitors. As the flow cytometry data 
(Figure 5.12) showed that the number of mitotic cells was very similar when 
Nocodazole was used alone or in combination with GSK461364, this provided a useful 
means by which to assess the PLK1 activity. Cells were therefore treated with DMSO, 
Nocodazole, Nocodazole and 5 nM GSK461364, Nocodazole and 10 nM GSK461364 
or Nocodazole and 20 nM GSK461364 for 4 or 8 hours.  
 
Figure 5.13 shows that as expected the levels of phosphorylated histone H3 at serine 10 
are increased in the Nocodazole and Nocodazole/ GSK461364 combination treatments 
compared to the DMSO control. The levels of phosphorylated histone H3 (S10) were 
fairly consistent throughout the different combinations of drug treatments. The 
phosphorylation of BubR1 showed that the levels decrease with increasing 
concentrations of GSK461364. However, this is the case independent of p53 status. 
There is therefore not a significant difference in PLK1 activity between the p53+/+ and 
p53-/- cells. This suggests the activity of PLK1 alone, does not account for the 
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differences observed between the two lines in regards to the assessments of mitotic 
events.   
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Figure 5.13. PLK1 activity in HCT116 p53+/+ and p53-/- cells upon treatment with PLK1 
inhibitors. HCT116 p53+/+ and p53-/- cells were treated with DMSO, 3.3 µM Nocodazole, or 3.3 µM 
Nocodazole in combination with 5, 10 or 20 nM GSK461364 for 4 hours (A) or 8 hours (B). Cells were 
subsequently harvested and western blotting was performed with the resulting cell lysates. 
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5.3.7. p53 plays a role in centrosome separation upon inhibition of PLK1 
	  
Once entry into mitosis is achieved, PLK1 is involved in the maturation and separation 
of centrosomes. The characteristic ‘polo’ arrest results as a consequence of the 
centrosomes failing to separate and migrate to opposite sides of the cell. This results in 
a monopolar spindle rather than the bipolar spindle required for successful separation of 
the chromatid pairs. Studies have linked p53 to the centrosomes for several years, both 
in terms of localisation and functions. The functions of p53 at the centrosomes are 
regulation of centrosome duplication and regulation of centrosome separation 
(Fukasawa et al., 1996; Tritarelli et al., 2004; Nam and van Deursen, 2014). Therefore 
to determine if the presence of p53 results in more successful separation of centrosomes 
upon PLK1 inhibition, compared to the absence of p53, immunofluorescence with 
centrosome staining was used. Cells were fixed and stained with a γ-tubulin antibody, a 
marker for the centrosome, and then Alexa-fluor secondary antibody and DAPI. The 
centrosomes were then visualised in mitotic cells and the number of cells with separated 
centrosomes versus non-separated centrosomes were counted. The resulting numbers 
under DMSO or PLK1 inhibitor treated samples can be seen in Figure 5.14 A. As can 
be seen, under DMSO conditions separation of centrosomes in mitotic cells occurs in 
nearly all the cells analysed and there is little difference between the p53+/+ and p53-/- 
cells. Upon treatment with GSK461364 the number of separated centrosomes in mitotic 
cells is significantly reduced in both the p53+/+ and p53-/- cells compared to the DMSO 
controls. However,  the number of separated centrosomes is much higher than the non-
separated in the p53+/+ cells, whereas in the p53-/- cells the converse is true. Figure 
5.14 B shows representative images of the staining. 
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Figure 5.14. Centrosome separation in HCT116 cells upon treatment with GSK461364. HCT116 
p53+/+ and p53-/- cells were treated with 20 nM GSK461364 or DMSO for 8 hours. Cells were 
subsequently fixed and stained with γ-tubulin antibody (a centrosome marker), followed by secondary 
staining with Alexa Fluor® 488 and DAPI. Fluorescence microscopy was then used to allow manual 
determination of the number of mitotic cells showing a normal bipolar spindle (separated centrosomes) or 
monopolar spindle (non-separated centrosomes). Over 100 cells were counted for each condition (scored 
by two independent individuals) for each repeat and the average percentages of separated v non-separated 
centrosomes were calculated and plotted as a bar graph. Statistical significance is determined by *p<0.05 
and ***p<0.001 (A). Representative images for each condition are shown in (B). White arrows indicate 
the non-separated centrosomes in mitotic cells. The scale bar represents 75 microns.  
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5.3.8. p53 influences the pathway involved in centrosome separation 
 
Due to the observed differences in centrosome separation between the p53+/+ and p53-
/- cells upon treatment with PLK1 inhibitors, the next aim was to investigate the 
pathway involved in centrosome separation. Centrosome separation is a two-step 
process, with the linker firstly being broken, and then a motor protein physically driving 
the centrosomes apart. PLK1 is involved in both of these steps. However, the motor 
protein required for the separation, Eg5, has inhibitors available, therefore allowing 
manipulation of the pathway. It is known that inhibition of Eg5 causes a similar mitotic 
arrest to inhibition of PLK1, with formation of a monopolar spindle. Therefore, to test if 
the differences in centrosome separation between the p53+/+ and p53-/- cells was 
dependent on PLK1 or a consequence of impairment of the pathway, STLC, an Eg5 
inhibitor was used. STLC targets the catalytic domain of Eg5 and inhibits both the basal 
and microtubule-activated ATPase activity of Eg5 (Skoufias et al., 2006). If the 
differences occurred between p53+/+ and p53-/- cells under inhibition of Eg5, this 
would suggest that the centrosomal pathway is affected by p53. HCT116 p53+/+ and 
p53-/- cells were treated with a range of doses of STLC and imaged over 16 hours at 
four minutes intervals. Analysis of the mitotic duration was carried out and as can be 
seen in Figure 5.15 use of the Eg5 inhibitor results in a similar phenotype to the PLK1 
inhibitors, with p53-/- cells showing a more severe mitotic arrest compared to the 
p53+/+ cells. This result is consistent with the idea that PLK1 is responsible for Eg5 
activation and that PLK1 inhibition would impair Eg5 activation. 
 
To then determine if inhibition of Eg5 showed p53-dependent sensitivity similar to that 
seen with the PLK1 inhibitors, an MTS assay was carried out with the HCT116 p53+/+ 
and p53-/- cells with a range of concentrations of STLC. Figure 5.16 A shows that the 
results mirror inhibition of PLK1, with increased comparative sensitivity to STLC in the 
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p53-/- cell line. Additionally, western blotting was carried out, with treatments of 24, 48 
or 72 hours. As can be seen in Figure 5.16 B the PLK1 levels throughout the treatment 
time course, show similar levels to that when PLK1 inhibitors are applied, with an 
increase in abundance of PLK1 at 24 hours of treatment. Similarly, p53 and p21 levels 
increase with treatment, and DNA damage occurs as shown by phosphorylated H2AX. 
This strongly suggests that the effects observed with PLK1 inhibitors are due to 
impairment of the centrosome separation pathway of which Eg5 is within. 
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Figure 5.15. p53 reduces the duration of mitotic arrest upon treatment with STLC. HCT116 p53+/+ 
(A) and p53-/- cells (B) were treated with 250 or 500 nM STLC or DMSO as a vehicle control. Time-
lapse analysis was then used to determine the duration of mitosis. Both graphs represent the cumulative 
data from 50 cells for one experiment and are representative of two replicates. 
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Figure 5.16. HCT116 p53+/+ and p53-/- cells treated with STLC. (A) HCT116 p53+/+ and p53-/- cells 
were treated with DMSO or 62.5, 125, 250, 500, 1000 or 2000 nM STLC. After 72 hours of treatment an 
MTS assay was used to determine cell survival. (B) HCT116 p53+/+ and p53-/- cells were treated with 
500 nM STLC for 24, 48 or 72 hours. Western blotting was then used with the antibodies indicated in the 
figure. 
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For these differences to emerge, p53 would either have to directly act on Eg5, or act on 
a pathway that can compensate for loss of Eg5. Studies have shown that Kif15, a 
functionally redundant motor protein of Eg5, can separate the centrosomes in the 
absence of Eg5 (Tanenbaum et al., 2009). Therefore, it was hypothesised that p53 may 
have an effect on Eg5 or the pathway involving Kif15. Therefore, the levels of Eg5 and 
Kif15 proteins were assessed in the HCT116 p53+/+ and p53-/- cells and the MCF-7 
wild type and p53 KO cells under basal conditions. Figure 5.17 shows that in both 
HCT116 and MCF-7, cells the levels of Kif15 appear to be slightly lower in the absence 
of p53, whilst Eg5 levels appeared to be p53-independent.  
 
	  
	  
Figure 5.17. Levels of Kif15 and Eg5 in p53 competent and p53 knockout cells. Untreated HCT116 
p53+/+ and p53-/- (A) and MCF-7 wild type and p53 knockout cells (B) were harvested and the cell 
lysate was analysed by western blotting.   
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As a result of the observation that the presence of p53 may affect the levels of Kif15, 
the next aim was to determine if either Kif15 or Eg5 are p53 inducible. In order to test 
this, the first experimental approach was to treat cells with the MDM2 inhibitor, Nutlin-
3, for up to six hours to induce a p53 response and assess whether the levels of Kif15 or 
Eg5 increased. As can be seen in Figure 5.18 whilst Nutlin-3 caused an induction in 
p53, there was no corresponding p53-dependent increase in either Kif15 or Eg5 levels. 
 
Whilst Nutlin-3 results in induction of p53, this occurs by inhibiting MDM2 and thus 
preventing the degradation of p53. Therefore, no DNA damage occurs, so we 
hypothesised that p53 may have to be induced by DNA damage to result in any 
observable differences in Kif15 or Eg5 levels. Two concentrations of etoposide were 
tested for six and sixteen hours of treatment. Figure 5.19 shows that again, as with 
Nutlin-3, there were no p53-dependent increases in Eg5 or Kif15 levels. Whilst Eg5 
levels fluctuated with treatment, this was not in a p53-dependent manner. 
 
At this point it seemed unlikely that Kif15 or Eg5 were p53 targets, either directly or 
indirectly. However, the p53-dependent differences that had been observed at the 
centrosomes occurred under inhibition of PLK1 or Eg5. As a final check, the Eg5 and 
Kif15 levels were tested under treatment with PLK1 inhibitors, GSK461364 or BI6727, 
and Eg5 inhibitor, STLC. Figure 5.20 shows that under all treatment types, in both the 
HCT116 p53+/+ and p53-/- and MCF-7 wild type and p53 knockout cells, the changes 
in Eg5 levels were independent of p53. Whilst the Kif15 levels appeared higher in the 
p53 competent lines, there was no obvious induction upon treatment with either PLK1 
or Eg5 inhibitors. 
 
Overall, these findings suggest p53 does not affect Eg5 or Kif15 levels upon treatment 
with a variety of drugs. Therefore, it seems unlikely that Kif15 is substituting for Eg5 in 
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a p53-dependent manner when the pathway involved in centrosome separation is 
inhibited. 
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Figure 5.18. Kif15 and Eg5 levels upon treatment with Nutlin-3. HCT116 p53+/+ and p53-/- cells (A) 
or MCF-7 wild type and p53 knockout cells (B) were treated with 10 µM Nutlin-3 for 0, 1, 2, 4 or 6 
hours. Cells were subsequently harvested, and analysed by western blotting with the antibodies indicated 
in the figure. 
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Figure 5.19. Kif15 and Eg5 levels upon treatment with etoposide. HCT116 p53+/+ and p53-/- (A+B) 
and MCF-7 wild type and p53 knockout cells (C+D) were treated with 25 µM (A+C) or 50 µM (B+D) 
etoposide. Cells were then harvested and analysed by western blotting with the antibodies indicated in the 
figure. 
	  
HCT116&
Eg5&
Ac,n&
p53&
Kif15&
p53&+/+& p53&5/5&
0&
h&
6&
h&
16
&h
&
0&
h&
6&
h&
16
&h
&
A"
C"
Etoposide&25&μM&
HCT116&
Eg5&
Ac,n&
p53&
Kif15&
p53&+/+& p53&5/5&
0&
h&
6&
h&
16
&h
&
0&
h&
6&
h&
16
&h
&
Etoposide&50&μM&
MCF57&
Eg5&
Ac,n&
p53&
Kif15&
WT& p53&KO&
0&
h&
6&
h&
16
&h
&
0&
h&
6&
h&
16
&h
&
Etoposide&25&μM&
MCF57&
Eg5&
Ac,n&
p53&
Kif15&
WT& p53&KO&
0&
h&
6&
h&
16
&h
&
0&
h&
6&
h&
16
&h
&
Etoposide&50&μM&
B"
D"
	   153	  
	  
	  
	  
	  
	  
	   	  
HCT116&
Eg5&
Ac,n&
p53&
Kif15&
p53+/+& p535/5&
N
T& 24
&h
&
48
&h
&
A"
GSK461364&20&nM&
DM
SO
&
72
&h
&
N
T& 24
&h
&
48
&h
&
DM
SO
&
72
&h
&
HCT116&
Eg5&
Ac,n&
p53&
Kif15&
p53+/+& p535/5&
N
T& 24
&h
&
48
&h
&
B"
BI6727&10&nM&
DM
SO
&
72
&h
&
N
T& 24
&h
&
48
&h
&
DM
SO
&
72
&h
&
MCF57&
Eg5&
Ac,n&
p53&
Kif15&
WT& p53&KO&
N
T& 24
&h
&
48
&h
&
C"
GSK461364&20&nM&
DM
SO
&
72
&h
&
N
T& 24
&h
&
48
&h
&
DM
SO
&
72
&h
&
MCF57&
Eg5&
Ac,n&
p53&
Kif15&
WT& p53&KO&
N
T& 24
&h
&
48
&h
&
D"
BI6727&10&nM&
DM
SO
&
72
&h
&
N
T& 24
&h
&
48
&h
&
DM
SO
&
72
&h
&
	   154	  
	  
	  
	  
	  
Figure 5.20. Kif15 and Eg5 levels upon treatment with PLK1 and Eg5 inhibitors. HCT116 p53+/+ 
and p53-/- cells (A,B+E) and parental MCF-7 and p53 knockout cells (C,D+F) were treated with PLK1 
inhibitors, GSK461364 (A+B) and BI6727 (C+D), and Eg5 inhibitor, STLC (E+F). PLK1 inhibitors were 
applied for 24, 48 or 72 hours, along with an untreated and DMSO treated sample, whilst STLC was 
applied for 0, 6 or 16 hours. After harvesting, cell lysates were analysed by western blotting using the 
antibodies indicated in the figure. 
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5.4. Discussion 
	  
The findings of this chapter firstly show that upon treatment with PLK1 inhibitors the 
p53 dependent subset of cells that accumulate in G1 result from cells completing 
mitosis. Use of cell synchronisation by serum starvation and flow cytometry proved 
useful in allowing determination of this finding. Ideally, other methods of 
synchronisation would be tested to confirm this result. Further investigations show that 
in p53 wild type cell lines the delay in mitosis is shorter upon application of PLK1 
inhibitors than in p53 deficient cell lines. This appears to be dependent on the DNA 
damage response pathway proteins ATM and ATR. As previously mentioned, ATM and 
ATR phosphorylate the serine 15 residue of p53 in response to cellular stress, such as 
DNA damage. Serine 15 has been shown to be a critical residue of p53 for its activation 
as a transcription factor (Loughery et al., 2014). Therefore, activation of p53 appears to 
be required for the response to PLK1 inhibitors. The differences in mitotic duration 
cannot be accounted for by a p53 dependent delay in mitotic entry. As p53 can induce a 
G2/M arrest in response to DNA damage, and as it was observed that PLK1 inhibitors 
led to DNA damage, a delay in mitotic entry seemed a plausible mechanism. If p53 
could delay entry into mitosis upon inhibition of PLK1, it may have allowed p53 to 
carry out transcriptional functions that may have been able to put a safety net in place 
before cells entered mitosis, where transcription is shut down (Gottesfeld and Forbes, 
1997). This could have resulted in the observation of p53 competent cells having a 
higher success rate of completing cytokinesis in the presence of PLK1 inhibitors than 
p53 deficient cells. However, the experiments completed here suggest that is not the 
case. Additionally, the same effect is not observed when PLK1 inhibitors are replaced 
with Taxol, therefore suggesting that p53 does not have an effect once the spindle is 
established. Taken together, this implicates a role for p53 in early mitosis.  
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A p53-dependent difference in the activity of PLK1 can also not be attributed to the 
effects observed. By arresting cells in mitosis with Nocodazole and then applying 
increasing doses of PLK1 inhibitor, the activity of PLK1 could be determined by 
observing a PLK1 target. Phosphorylation of BubR1 at threonine 680 was used as a 
PLK1 target (Suijkerbuijk et al., 2012). However, phosphorylation at this site showed 
no significant difference in activity of PLK1 between p53 competent or deficient cells. 
Therefore, it seemed unlikely that the mitotic effects observed were simply due to 
higher levels of activity of PLK1 in p53 competent cells leading to the same dose of 
PLK1 inhibitor having less effect on the p53 wild type lines. 
 
The results presented here also show that p53 promotes centrosome separation when 
PLK1 is inhibited, due to the observation that a p53 wild type line has a greater 
proportion of separated centrosomes than a p53 deficient line when treated with 
GSK461364. Furthermore, inhibiting a downstream target of PLK1 that is involved in 
centrosome separation, the motor protein Eg5, results in a similar p53 dependent 
phenotype as inhibition of PLK1. This is the case in regards to the mitotic duration 
observed under the inhibition of Eg5 and the sensitivity to Eg5 inhibition. 
 
The mechanism by which p53 exerts these effects is currently unknown. One hypothesis 
is that p53 regulates the levels of Eg5 or a functionally redundant motor protein, Kif15. 
As Kif15 has previously been shown to substitute for loss of Eg5 (Tanenbaum et al., 
2009), in maintaining efficient centrosome separation, this seemed a plausible idea. 
However, experimental procedures indicated that neither Eg5 nor Kif15 proteins were 
p53 inducible. Treatment with Nutlin-3 (allowing activation of p53 without DNA 
damage) and etoposide (resulting in p53 activation by DNA damage) both failed to 
produce p53 dependent effects in regards to the Eg5 or Kif15 levels. Similarly, 
treatment with PLK1 inhibitors or an Eg5 inhibitor, where the p53-dependent effects are 
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actually observed, also failed to result in any Eg5 or Kif15 differences. With thorough 
testing through use of several types of p53 activators, it could be concluded that Eg5 
and Kif15 are not direct transcriptional targets of p53. However, activity of these 
proteins, or differences in their regulators and partners was not tested, which may prove 
useful to further investigate this hypothesis. 
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Chapter 6 : Conclusions and Future 
Perspectives 
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Figure 6.1. Conclusion summary. The overall findings of this thesis are represented in the schematic. 
As PLK1 is involved in a phosphorylation cascade that leads to activation of Eg5, inhibition of PLK1 or 
Eg5 show similar outcomes. Their inhibition or silencing leads to DNA damage, which results in 
activation of p53 through phosphorylation of the serine 15 residue of p53 by the DNA damage response 
pathway proteins, ATM and ATR. The presence of p53, when PLK1 or Eg5 is inhibited, leads to 
improved centrosome separation and a mitotic transition more comparable to the homeostatic normal, 
compared to the absence of p53. This results in an increase in the number of cells completing cytokinesis 
and returning to G1 with 2N DNA content, and overall results in an increased survival and decreased 
sensitivity to PLK1 and Eg5 inhibitors in comparison to the absence of p53.  
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The overall findings and conclusions of this thesis are represented in Figure 6.1. The 
findings support the findings of previous studies that show a reduced sensitivity of 
PLK1 inhibitors to cancer cells expressing wild type p53 (Guan et al., 2005; Liu, Lei 
and Erikson, 2006; Sur et al., 2009; Degenhardt et al., 2010; McKenzie et al., 2010; 
Danovi et al., 2013; Yim and Erikson, 2014). Furthermore, the findings show that PLK1 
inhibitors mainly arrest cancer cells in mitosis, result in DNA damage, and lead to 
cancer cell death or mitotic slippage, again supporting previous studies (Hyungshin Yim 
and Erikson, 2009; Driscoll et al., 2014). However in addition to this, the results 
presented in this thesis show that a greater proportion of p53 competent cells can 
successfully complete cytokinesis in the presence of PLK1 inhibitors, than p53 null 
cells treated with the same dose. This adds to a previous study, which showed inhibition 
of Aurora A, an upstream activator of PLK1, resulted in an increased delay in mitotic 
exit in p53 deficient lines compared to p53 wild type cells (Marxer et al., 2014). The 
results shown here further these findings, by showing these effects appear to be ATM 
and ATR dependent, as well as p53-dependent, suggesting that activation of p53 is 
required for this effect to occur. Inhibition of ATM and ATR, with small molecule 
inhibitors KU-55933 and VE-821, resulted in a reduction in the levels of p53 and 
phosphorylated p53 at residue serine 15, and resulted in a further increase in mitotic 
duration upon treatment with PLK1 inhibitors, therefore ablating the protective effect. 
The activation of p53 could be therefore be through the DNA damage response 
pathways in response to the DNA damage observed by inhibition of PLK1 or this effect 
may be due to basal levels of p53 activity. Previous work in the Meek lab showed that 
ATM and ATR maintain a low basal level of p53 serine 15 phosphorylation in cultured 
cancer cells that is required for p53 dependent transactivation in the absence of 
exogenous cell stress, such as DNA damaging agents (Loughery et al., 2014). Therefore 
it is currently unknown whether an activating stimulus, such as the PLK1 inhibitor 
	   161	  
induced DNA damage, is required for the p53-dependent activation and effects or if the 
basal levels of phosphorylated p53 alone are sufficient. 
The results shown here further explore the roles of p53, by honing in on the action of 
p53 in mitosis. The experimental procedures utilised, whilst not confirming the full 
mechanism, have narrowed the areas in which p53 can act. By showing that p53 does 
not delay mitotic entry, and the fact that interfering with the depolymerisation of 
microtubules (through use of Taxol) does not result in a p53 dependent outcome, the 
role of p53 has been implicated in early mitosis.  Due to PLK1 being involved in 
centrosome separation during early mitosis, this aspect of its function was warranted for 
investigation. As a result of this investigation the data presented in this thesis also 
shows a potential novel role for p53 in the separation of the centrosomes. Previous 
studies have suggested a role for p53 in centrosome integrity. However, this has been 
suggested to be through p53 repressing the stimulation of centrosome separation by 
Cyclin B2, therefore, resulting in a p53-dependent down-regulation of centrosome 
separation. Cyclin B2 overexpression was shown to induce hyperactivation of PLK1 
through Aurora A, thus resulting in an acceleration of centrosome separation. The same 
study showed that p53 acted antagonistically to Cyclin B2 in normal cells, by 
controlling Aurora A (Nam and van Deursen, 2014). The results shown in this thesis 
suggest that there is another mechanism in this pathway in which p53 can actually 
stimulate the separation of centrosomes when the pathway involved in stimulation of 
centrosome separation is inhibited. To further this work, the mechanism by which p53 
has such an effect on the centrosome separation pathway should be investigated. 
 
How p53 would exert such a role in mitosis is currently unknown. Although Cyclin B1 
was shown to be transcribed during mitosis in Hela cells (Sciortino et al. 2001), it is 
generally accepted that transcription shuts down during mitosis. This is due to the 
chromatin being highly condensed, so transcription is near impossible as promoters are 
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inaccessible and specific RNA polymerase II factors are displaced from the 
chromosomes (Gottesfeld & Forbes 1997). Based on this, it seems unlikely that p53 
would be able to transcriptionally activate the expression of target genes during mitosis. 
Therefore, p53 may be able to carry out a transcription-independent function in mitosis 
in response to centrosomal problems, or there may be a p53-dependent compensatory 
pathway that comes into play when mitotic problems are encountered. 
 
Eg5 is the motor protein that has been shown to drive the centrosomes apart in nearly all 
tested organisms (Ferenz, Gable and Wadsworth, 2010). However, in the event of 
inhibition of Eg5, Kif15 has been shown to substitute for the lack of Eg5 (Tanenbaum et 
al., 2009). As inhibition of Eg5 by STLC resulted in a similar p53 protective effect to 
that of inhibition of PLK1, the p53 protective effect may have occurred through either 
Eg5 or Kif15 levels being stimulated by p53. However, preliminary data suggested that 
neither Eg5 nor Kif15, two motor proteins involved in the separation of centrosomes, 
are direct transcriptional targets of p53. Treatments with Nutlin-3, etoposide, PLK1 
inhibitors (GSK461364 or BI6727) or Eg5 inhibitor (STLC), did not result in a p53-
dependent change in the total levels of Eg5 or Kif15 proteins. This suggested that the 
levels of these motor proteins are not affected by p53, although for a more thorough 
investigation the activity and localisation of these proteins could also be tested, to 
determine if either protein was more active in p53 competent cells or if p53-dependent 
differences in localisation occured. Similarly, whilst Eg5 and Kif15 may not be direct 
transcriptional targets of p53, a compensatory effect may involve p53-dependent 
regulation of regulators or partners of these proteins. Additionally, dynein, a third motor 
protein that is also involved in centrosomal forces, could be a potential p53 target 
candidate. Studies have suggested that all three motor proteins are required to act 
together to generate the correct force balance in the spindle (vanHeesbeen, Tanenbaum 
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and Medema, 2014). Therefore, future work could investigate if dynein is a 
transcriptional target of p53.  
 
In regards to the sensitivity differences observed that are dependent on the p53 status of 
cancer cells, further work could be carried out. As this has only been shown in cell lines 
it would be interesting to test if this holds true in vivo. There has been a wealth of 
clinical data generated through the clinical trials testing PLK1 inhibitors. One clinical 
trial study showed that the response to BI6727 was independent of the genetic subgroup 
(Döhner et al., 2014). However, p53 status was not one of the factors that was assessed. 
Access to the patient data would be very beneficial to assess whether there is an 
association between responders versus non-responders in regards to their p53 status.  
 
Determination of the surviving cells would also assist in improving treatment options 
for patients. The data here indicate that there is a subpopulation of cells that manage to 
complete mitosis successfully, to return to G1, in a p53-dependent manner. These cells 
are the most plausible source of survival upon treatment with PLK1 inhibitors. 
However, this has not been proven. By sorting the treated cells, perhaps this could be 
tested. By knowing what cells are the source of survival, and thus resistant to these 
inhibitors, a targeted combination treatment could be used. Different chemotherapeutic 
drugs are effective in different stages of the cell cycle. Therefore, knowing where the 
surviving cells are likely to be in the cell cycle may assist in improving efficacy of 
PLK1 inhibitors in combination with another chemotherapeutic agent. 
 
The later part of this research suggested that effects observed with PLK1 inhibitors were 
also observed with Eg5 inhibition. This would indicate that the same pathway is 
affected by both these types of inhibitors. This could then suggest that assessment of 
patients for their p53 status may not only be beneficial for PLK1 inhibition, but also for 
Eg5 inhibition. In order to further test this, combining a PLK1 inhibitor with an Eg5 
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inhibitor, and looking for any additive effects, would allow determination of whether 
only the same pathway was affected. Any inhibitors of other proteins involved in 
centrosome separation could also be tested for similar p53-dependent effects. As only 
Eg5 was investigated, it would be useful to determine if similar effects are observed 
with depletion of proteins involved in the centrosome disjunction pathway. Overall this 
could prove to be very important information to obtain, as it could impact on the 
treatment of patients. A better understanding of how the p53 status and drugs directed at 
PLK1, and other proteins involved in the centrosome separation pathway, are related is 
required for ensuring the best treatment options are available to the diverse range of 
cancer patients requiring treatment. 
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The disc contains four live-cell imaging movies relating to Figure 5.8. HCT116 p53+/+ 
and p53-/- cells stained with SiR-DNA were imaged every four minutes over 
approximately 16 hours. The four movies included on the disc are: 
1. HCT116 p53 +/+ cells treated with DMSO 
2. HCT116 p53+/+ cells treated with 20 nM GSK461364 
3. HCT116 p53-/- cells treated with DMSO 
4. HCT116 p53-/- cells treated with 20 nM GSK461364. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
